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Abstract 
 Significant work has been done studying the metabolism of adipose tissue in 
recent years, in an effort to more effectively combat the obesity epidemic. Adipose tissue 
has been found to participate in the metabolism signaling network, with BCAAs playing 
a vital role as messengers relating the amino acid content of high protein meals. BCAA 
plasma levels have also been found to be elevated in individuals with obesity or type 2 
diabetes, with their increased levels often occurring prior to elevated resting glucose 
levels and insulin resistance. Their dynamics under various metabolic conditions must 
still be examined however, on a metabolically relevant time scale. Current methods are 
limited in their time response for in vivo studies, with time-points ranging from minutes 
to hours. Metabolic dynamics must be studied in near real time, in order to establish these 
bioamines as metabolic biomarkers. 
In this work, an in vivo platform is developed for monitoring bioamine 
metabolism dynamics in adipose tissue and skeletal muscle with 22 second temporal 
resolution. A high-speed online microdialysis-CE assay, capable of detecting BCAAs and 
their related metabolites, is utilized to monitor dynamics in near real time. Inguinal 
adipose tissue and quadriceps skeletal muscle serve as the sampling locations in C57BL6 
mice. A systemic stimulation of insulin demonstrated our assay’s ability to detect induced 
metabolic dynamics. Stimulations of glucose, saccharin, and ace K provide further 
information regarding the metabolism of bioamines in adipose tissue.  
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1.1 The Obesity Epidemic 
1.1.1 Obesity and Adipose Tissue 
 Obesity is a widely prevalent health epidemic in the United States, with nearly 
70% of adults labeled as obese or overweight.1,2 Obesity is generally defined as the 
unproportioned accumulation of adipose tissue resulting from an energy imbalance, 
where the energy intake of an individual is greater than the energy spent. Total energy 
expenditure is comprised of active energy and resting energy, the latter of which 
describes the thermic effect of metabolism.3 Traditional methods of reducing energy 
intake through restricted diet and increasing total energy expenditure through physical 
activity have proven insufficient in effectively curbing this epidemic. Therefore current 
research has focused on more fully understanding this disease’s development and 
mechanisms. 
 Brown adipose tissue (BAT), white adipose tissue (WAT), and beige adipose 
tissue are all found throughout the body.4-6 BAT usually contains one large lipid vesicle 
and contains high amounts of mitochondria with uncoupling protein-1 (UCP1).6 Its 
primary role is thermogenesis.7 WAT contains multiple smaller lipid vesicles utilized as 
storage for excess triglycerides until needed for gluconeogenesis.8,9 This was assumed to 
be WAT’s sole responsibility, until recently it was discovered that it plays an active role 
in the signaling network with the brain, liver, muscle, and pancreas.10-12 Participation in 
this signaling network to relay information regarding energy balance and appetite, 
suggests WAT should be classified as an endocrine organ.13,14 Beige adipose tissue 
describes clusters of adipocytes which form in WAT, but have similar lipid droplet 
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conformation to BAT and contain UCP1. These clusters also have thermogenic 
capabilities.6,15 
 The accumulation of WAT during obesity is due to both an increase in the number 
of adipocytes present and their expansion. Size expansion of adipocytes is believed to 
aide in the progression of disease development.16,17 Adverse health effects related to 
obesity include, but are not limited to, type 2 diabetes, hypertension, and heart disease.18  
 Adipocytes have been found to regulate several small molecules acting as 
messengers to relate energy functions throughout the body.19 These small molecules, the 
branched chain amino acids (BCAAs) – leucine, isoleucine, and valine – are utilized by 
adipocytes for the citric acid cycle and lipogenesis.19,20 Complete understanding of 
adipose tissue’s role in the regulation of various small molecule messenger mechanisms 
could yield insight into potential dysregulation leading to the development of obesity.  
 
1.1.2 Branched Chain Amino Acids 
 The BCAAs (Figure 1.1), promote metabolism due to a spike in their plasma 
levels following a high protein meal. The increase in plasma BCAA levels is due to the 
liver’s poor ability to metabolize them as they pass through. Plasma BCAAs are then able 
to regulate insulin secretion from the pancreas,21 protein synthesis and degradation in 
muscle,12 and food uptake control in the brain.11,20  
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Figure 1.1. The branched chain amino acids: (A) leucine, (B) isoleucine, and (C) valine. 
 
The first step in BCAA catabolism requires the enzyme mitochondrial branched chain 
aminotransferase (BCAT2), which is present only at very low levels in the liver.22,23 This 
reversible transamination conversion yields α-ketoacids for each respective BCAA with a  
Glutamate 
Leucine 
Isoleucine 
Valine 
α-Ketoglutarate 
Branched-Chain 
Aminotransferase 
(BCAT2) 
α-ketoacids 
NAD
+
 
NADH + H
+
 
CoA-SH 
CO
2
 
Branched-Chain Ketoacid Dehydrogenase 
Complex (BCKDHC)  
Acetyl-CoA products 
Alanine 
Pyruvate 
* 
Figure 1.2. The BCAA catabolism cycle. Acetyl CoA products are utilized in the citric acid cycle, and 
downstream products of glutamate and alanine are also present. *Glutamate-pyruvate transaminase. 
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by-product of glutamate. These α-ketoacids then react with branched chain ketoacid 
dehydrogenase complex (BCKDHC) in an irreversible and rate limiting oxidative 
decarboxylation yielding acetyl-CoA products. Alanine is a by-product of the glutamate 
to α-ketoglutarate conversion.24 The catabolism cycle has been shown to operate as a 
feedback loop, in which BCAAs themselves can act as inhibitors when an imbalance 
arises.25 
Circulating levels of BCAAs have been found elevated in individuals affected by 
obesity or type 2 diabetes.21,26-29 Upon weight loss, either naturally or by gastric bypass 
surgery, circulating levels returned to normal.30 This confirmed the ability of adipose 
tissue to regulate these small molecule messengers.30,31 Since elevated circulating BCAA 
levels often appear prior to elevated fasting glucose levels and insulin resistance, it has 
been determined these are one of the best predictors for metabolic disorders, including 
diabetes.21,28 
 
1.1.3 Adipose Tissue Research Models 
 The prevalence of obesity has prompted both in vitro and in vivo analysis of 
adipose tissue. In vitro models most commonly use 3T3-L1 or 3T3-F422A cell lines.32,33 
Both cells lines originate from a 3T3 mouse, and then are differentiated to adipocytes 
under specified conditions.34-37 While in vitro analysis avoids the complexities of an in 
vivo model, it does not allow for interworking bodily systems to be assessed. Within the 
human body, especially in regards to metabolism and metabolic dysregulation, adipose 
tissue does not function in isolation. It is part of a vast signaling network,13,14 and to best 
replicate this scenario for analysis, in vivo models must be employed. Several rodent 
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models, along with human studies, have been utilized for obesity research.38,39 Tissues 
are frequently excised and examined ex vivo,40 however this does not allow for dynamic 
changes to be monitored. C57BL6 mice are commonly studied in obesity research due to 
the progression of their metabolic dysregulation mimicking that of humans.41 Therefore, 
this model is an ideal choice for investigating dynamic changes occurring within 
metabolism.  
 
1.2 Microdialysis Sampling 
1.2.1 Probe Design and Function 
 Microdialysis probes are one of the preferred sampling techniques for in vivo 
studies due to minimal tissue disturbances at the tissue or organ of interest.42,43 As shown 
in Figure 1.3, microdialysis probes of side-by-side 
geometry are constructed by inserting two narrow bore 
fused-silica capillaries into a hollow fiber 
semipermeable dialysis membrane.42-44 The two 
capillaries, acting as inlet and outlet channels, are offset 
to create a sampling region. Sampling regions typically 
range from 3-10 mm in length, for use in in vivo versus 
in vitro studies respectively.45-48 Perfusate, the solution 
pumped through the inlet channel, is chosen to mimic 
the composition of the external matrix surrounding       
Perfusate 
Dialysate 
Sampling 
Region 
Figure 1.3. Schematic of a 
microdialysis probe with side-by-
side geometry. 
 
7 
 
the probe in both pH and ionic composition. Matching the composition of the perfusate 
with the surrounding matrix allows analytes of interest to diffuse across the dialysis 
membrane due to a concentration gradient. Solution containing the sampled analytes, 
termed the dialysate, is then carried out through the outlet channel.43,49 
 Initial microdialysis probes were designed primarily for use in neuroscience 
research, consisting of a dialysis membrane located at the end of a rigid spherical 
cannula.50 The rigid cannula was fashioned to be implanted through a guide cannula, 
which was screwed to the skull to hold the dialysis membrane securely in place (Figure 
1.4A). This style functioned well for neuroscience experiments, however the rigidity was 
disadvantageous when working with other soft tissues. Furthermore, awake experiments 
ran the risk of puncturing the surrounding tissue with the rigid cannula. To address these 
concerns, a flexible cannula design was fashioned for intravenous sampling (Figure 
1.4B).51-53 The flexible design allowed the probe to be inserted away from any interfering 
movements of an awake animal and decreased the chances of puncturing blood vessel 
walls. 
 While the flexible probe design was successfully implemented for intravenous 
studies, it still damaged other soft tissues.43 Linear probes were developed and 
successfully utilized in tumor tissue,1,54,55 muscle,54,56 liver,57-59 and dermis60-62 
experiments (Figure 1.4C). The primary advantage of the developed design was the direct 
contact between the dialysis membrane and soft tissue, allowing for close proximity 
diffusion of analytes. 
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Figure 1.4. Schematic of various microdialysis probe designs. (A) A rigid cannula design inside a guide 
cannula, (B) an intravenous sampling dialysis probe, and (C) a linear probe intended for sampling of soft 
peripheral tissues. 
 
 All microdialysis probe designs serve as a continuous sampling technique with no 
net loss of surrounding extracellular fluid. The semipermeable dialysis tubing allows for 
diffusion of small molecules, with a specific molecular weight cutoff (MWCO) that can 
be selected based on the expected biological matrix.63 In this way, microdialysis sampling 
enables continuous monitoring of biological phenomena in various tissues, while acting 
as a purification step to prevent large molecules from being collected.  
 
1.2.2 Recovery and Resolution 
 One of the fundamental limitations of microdialysis sampling is that equilibrium 
is never established across the membrane, and thus the recovered concentration in the 
dialysate is a fraction of the concentration in the extracellular matrix.49 Even at typical 
flow rates between 0.1-1.0 µL/min, equilibrium is still not reached, leading to an inability 
to acquire absolute quantification.64 The description of collected analyte in the dialysate 
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can be defined as either absolute or relative recovery. Absolute recovery is the total 
amount of analyte that is collected in the perfusion medium, per rate of time. Relative 
recovery is the amount of analyte that is collected in perfusion medium relative to the 
amount of analyte present in the extracellular matrix.49  Perfusion rates dramatically 
effect both recoveries, with decreased flow rates into the probe yielding increased relative 
recovery and decreased absolute recovery, as shown in Figure 1.5.63,65,66 
 
Figure 1.5. The absolute and relative recoveries as a function of flow rate from a microdialysis probe. 
Adapted from Ref. 63. 
 
 A mathematical representation of relative recovery as a function of various 
experimental parameters is defined as: 
                                              RR = 
Cd
Ce
 = 1 - e
1
Qd(Rd+ Rm+ Re)                                       (1.1)       
Bungay et al. defined relative recovery, the fraction of analyte concentration in the 
dialysate (Cd) compared to the analyte concentration in the extracellular matrix (Ce), in 
terms of perfusion flow rate (Qd) and resistance to solute movement in the dialysate, 
through the probe membrane, and in the tissue/solution (Rd, Rm, and Re, respectively).
67 
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Solute movement in the dialysate and through the probe membrane depends on factors 
such as flow properties of the dialysate through the probe membrane, diffusion 
coefficient of analyte through membrane, chemical interactions occurring between the 
probe membrane and analyte, analyte diffusion in the membrane, and the probe 
membrane’s length, radius, and material.68,69 Analyte movement in the tissue is 
dependent on the diffusion through the extracellular matrix to the probe.68,70 
 The relative recovery of the microdialysis probe must be calculated to relate the 
collected concentration of analyte back to the actual extracellular concentration. When 
undergoing in vitro studies, probe calibration can proceed by creating calibration curves 
from known concentrations of solution with a microdialysis probe and comparing these 
signals to those obtained through direct injection of identical concentrations.71-73 Due to 
the fact that in vivo recoveries are typically less than in vitro results, in vitro probe 
calibration does not accurately predict in vivo results.74,75 In vivo recoveries are subject to 
the influences of uptake/release mechanisms during an analyte’s diffusion to the probe, as 
well as a more tortuous path of diffusion through tissue and extracellular space.76  
 Many in vivo calibration techniques have been employed such as retrodialysis, no-
net-flux, and perfusion flow rate (also known as “zero flow rate”). Retrodialysis involves 
adding an internal standard to the perfusion solution, and the amount of internal standard 
delivered through the microdialysis probe to the tissue is assumed to be equivalent to the 
analyte of interest’s diffusion efficiency into the dialysate.77,78 No-net-flux determines the 
diffusion of analyte into the dialysate as a function of perfusate solution 
concentrations.79,80 Zero flow rate monitors the concentration of analyte in the dialysate 
as a function of perfusion flow rate. Using a nonlinear regression, the concentrations of 
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the extracellular matrix can then be approximated.66,75,81 Probe calibration is a laborious 
process and for most in vivo experiments, the relative recovery may not be accurately 
predicted. Relative changes are most often assessed for in vivo microdialysis sampling, 
thus negating the need for absolute concentrations.43 
 Complications often encountered with microdialysis sampling include limitations 
on the spatial and temporal resolutions achieved. The potential for surrounding tissue 
damage due to probe implantation causes spatial resolution to be an important 
consideration in vivo. Spatial resolution is also negatively impacted in vivo when probes 
are operated at higher flow rates, usually to improve absolute recovery, causing an 
increased concentration gradient extending outwards from the probe’s location. The 
probe’s sampling region is also limited to ~1-5 mm in vivo, further affecting spatial 
resolution.74,82 
 Temporal resolution is defined as the smallest amount of time it takes an 
analytical system to detect changes in analyte concentrations. This is determined by the 
microdialysis probe flow rates as well as the parameters of the analytical system.64 To 
increase the efficiency of probe sampling, a slower perfusion rate is utilized, which 
results in longer sampling times. These longer sampling times decrease temporal 
resolution. When the dynamics being investigated occur on a slower timescale than probe 
sampling and instrument analysis time, the temporal resolution is simply the time 
required for signal intensity to increase from 10-90%, also known as the rise time.63 
Optimization between sample volume requirements, perfusion rate, and detection limits 
determines the temporal resolution attained.64    
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1.2.3 Coupling Microdialysis to an Analytical System 
 Despite their limitations, microdialysis probes remain heavily utilized as a 
sampling technique. Through offline and online analysis, analytical systems such as   
liquid chromatography (LC),83-86 capillary electrophoresis (CE),71,74,87,88 microchip 
electrophoresis,89,90 mass spectrometry (MS),91,92 and biosensors93,94 have been coupled 
to microdialysis sampling, just to name a few. Microdialysis sampling is a continuous 
sampling technique while analytical systems typically require discrete samples for 
analysis, which pairs well for offline fraction collection. Offline fraction collection 
utilizes microdialysis to collect aliquots of sample, which are then subsequently run on an 
analytical system. This method is limited in its time response, as enough sample aliquot 
must be collected for the selected analytical system’s volume requirements, as well as the 
potential for errors when handling such small volumes. Online analysis is highly 
desirable however, due to microdialysis sampling requiring no purification step prior to 
introduction onto an analytical system. An injection interface had to be designed to 
convert continuous dialysate flow from the probe into discrete sample plugs suitable for 
analysis on an analytical system.  
 Jorgenson and Lemmo utilized a flow-gate interface in the early 1990’s to couple 
size exclusion chromatography (SEC) with capillary zone electrophoresis (CZE).74,95 
Lada and Kennedy adapted this design for use in microdialysis and CZE.74 Two steel 
plates were separated by 75 µm of polytetrafluorethylene (PTFE), or Teflon. An inlet and 
outlet channel were incorporated into the PTFE for CE buffer, which ran perpendicular to 
channels positioned for the microdialysis probe outlet and CE separation capillary inlet. 
While CE buffer was flowing, dialysate samples were carried away and not injected onto 
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the separation capillary. To make an injection, voltage and buffer flow was stopped to 
allow sample volume to accumulate by the separation capillary inlet. Application of 
voltage then injected the dialysate sample. This interface yielded good temporal 
resolution, however it suffered from lack of reproducibility.64 
 Jorgenson and Hooker developed a new flow-gate interface using polycarbonate 
polymer for micro-HPLC and CZE.96 As 
shown in Figure 1.6, the clear polymer 
allowed for easy visualization of capillary 
alignment, making construction much more 
reproducible. It’s utilization in coupling 
microdialysis to high-speed analysis, 
especially CE,97-99 led to slight modifications in 
construction materials. A Plexiglas block with 
solenoid valve98 and a pneumatically actuated 
valve with polycarbonate48 or acrylic44 flow-gate interfaces have all been reported. In 
each of these designs, the reaction capillary, carrying the dialysate sample, and CE 
separation capillary are set 30-50 µm apart. Separation buffer is then pumped across the 
flow gate perpendicular to the fixed capillary positions to prevent dialysate from entering 
the inlet of the separation capillary. To inject a sample volume, flow of buffer is stopped 
using the valve and dialysate is allowed to accumulate in the gap between capillaries. 
After a delay, voltage is applied to the outlet of the separation capillary to pull the sample 
plug down into the capillary to begin separation. Buffer flow is then resumed to prevent 
any additional sample from entering the separation capillary. 
A 
C 
B 
D 
Figure 1.6. Schematic of the flow gate 
designed by Jorgenson and Hooker. The 
reaction capillary (A) and separation 
capillary (B) are spaced ~50 µm apart, 
with buffer flowing perpendicularly 
across the channel (C-D). 
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 Online coupling of microdialysis probes to analytical system, due to the 
development of flow-gated interfaces, allows for more near real time analysis of events, 
which is highly advantageous when studying biological phenomena.100 Temporal 
resolution of the overall system is now limited by the mass sensitivity, volume 
requirements, and analysis time of the instrument. When coupled with microdialysis 
sampling, HPLC’s femtomolar limits of detection (LODs) result in 5-30 minute sampling 
times. CE’s mass sensitivity and small volume requirements, attomolar LODs88 and 1-10 
nL of injected sample,64 allow for temporal resolutions on the order of 10-30 
seconds.45,47,101 As low as a 5 second temporal resolution has been reported by Lada and 
Kennedy.97 
 The implementation of flow-gated interfaces have allowed for the online coupling 
of microdialysis sampling to an analytical system by converting continuous dialysate 
flow into discrete samples. The mass sensitivity and small volume requirements make CE 
an advantageous coupling for this sampling technique, while high-speed CE’s fast 
analysis times yield temporal resolutions on the timescales of seconds. This is a clear 
advantage for the near real time analysis of biological phenomena. The primary limitation 
of coupling microdialysis online to CE is the sensitivity required for the detection scheme 
as a result of the small volumes being analyzed.102  
 
1.2.4 Analyte Derivatization and Detection 
 Several detection methods have been used in conjugation with microdialysis 
(MD)-CE including ultraviolet (UV),103 electrochemical (EC),104 and laser induced 
fluorescence (LIF)105 detection. LIF provides the best mass sensitivity for coupling with 
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MD-CE,106 however since most analytes in biochemical systems are not natively 
fluorescent, a derivatization scheme must be employed. Derivatization protocols focus on 
minimizing the limitations of labeling reactions such as the occurrence of fluorescent by-
products and long derivatization times that delay recording a biological event in near real 
time. 
 Fluorescein-5-isothiocyanate (FITC),107 naphthalene-2,3-dicarboxyaldehyde 
(NDA),108 and opthalaldehyde (OPA)44,98,109,110 have all been previously employed in 
MD-CE analysis. FITC’s long reaction times made it an undesirable reaction scheme, 
particularly when conducting in vivo experiments.48 NDA and OPA overcame reaction 
time limitations, with effective reactions in under 1 minute,111 however their 
disadvantages made their repeated use in online MD-CE assays challenging. NDA 
required separate store from cyano ions due to interactions yielding cyanohydrin 
intermediates, which produce fluorescent degradation products108 and OPA suffered from 
absorbance in the near UV48, photo-bleaching, and instability.112 Dr. Michael Bowser’s 
lab sought to employ 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBDF) as a labeling reagent 
to overcome previously encountered limitations. Use of NBDF was investigated due to its 
labeling of primary and secondary amines, as well as its excitation wavelength being 
compatible with common 488 nm argon ion and diode-pumped solid state lasers.48 Figure 
1.7 demonstrates the reaction scheme of NBDF with primary and secondary amines. 
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Figure 1.7. Derivatization reaction of NBDF with primary and secondary amines. 
 
 Although typical NBDF reaction times fluctuate around one hour at room 
temperature,113 a complete reaction was achieved in 5 minutes by utilization of a water 
bath to heat the reaction capillary to 80 ºC during the online derivatization.48 The primary 
limitation with the described derivatization scheme remains the hydrolysis by-product 
observed in CE-LIF separations. 
 In an effort to further increase the sensitivity of CE-LIF analysis, a sheath flow 
cuvette was introduced to the system. Buffer 
flows along the outside of the separation 
capillary as depicted in Figure 1.8. Streaming 
buffer pulls analytes into a laminar flow 
profile as they elute from the capillary.114 
Advantages of this system include no change 
in refractive index between the buffer and 
sample stream and reduced laser scatter, 
contributing to a reduced background and 
Figure 1.8. Schematic of a sheath flow 
cuvette design.  
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increased sensitivity. Sensitivity of the overall system was found to improve 15 fold 
through the implementation of a sheath flow cuvette.98  
 
1.3 Scope of Thesis 
 The importance of adipose tissue and BCAAs in overall body metabolism and 
their potential use as biomarkers for metabolic dysregulation has only recently been 
realized. To elucidate their potential, their complete role in metabolism must be fully 
understood. Monitoring metabolism dynamics as they occur is the only way to 
comprehend the processes at play, however current research has been limited in its 
temporal resolution.  In this work, we describe the development of an online MD-CE 
platform for the near real time analysis of BCAAs and their metabolites in vivo. 
 Chapter 2 describes the optimization of an online MD-CE assay for near real time 
monitoring of bioamines, particularly BCAAs and their metabolites. A temporal 
resolution of 22 seconds was able to be achieved, while still maintaining separation of 
leucine, isoleucine, and valine. An in vivo protocol for the sampling of adipose tissue and 
skeletal muscle was designed in Chapter 3. Parameters such as animal model, sampling 
locations, anesthetic regimes, surgical procedures, and euthanasia protocols were 
designed to allow for a variety of experiments to determine BCAAs’ role in overall body 
metabolism. Chapter 4 presents the successful implantation of microdialysis probes in 
inguinal adipose tissue and quadriceps skeletal muscle. The amino acid signature and its 
reproducibility for each tissue is established. Chapter 5 describes the initial stimulation 
experiments in adipose tissue and skeletal muscle, utilizing both glucose and artificial 
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sweeteners. A summary of completed work and potential opportunities for future 
direction of the developed platform are outlined in Chapter 6.  
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Chapter 2 
Characterization of Microdialysis – Capillary  
Electrophoresis Assay 
 
 
 
 
Sections adapted from: 
 “Weisenberger, M.M and Bowser, M.T. Anal. Chem. 2017, 89 (1), 1009-1014.” 
Reproduced with permission 
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2.1 Summary 
 In this work, a high-speed CE instrument coupled with online microdialysis 
sampling was optimized to yield the fastest temporal response possible while still 
providing separation of BCAAs and related metabolites. Parameters such as separation 
assay performance, reproducibility, LODs, temporal resolution, and relative recovery 
were assessed to ensure the assay’s suitability for in vivo experimentation. The separation 
assay was able to separate and detect all bioamines of interest, with reproducibility 
established over time periods anticipated for in vivo studies. LODs were estimated to be 
1.7 µM for glutamate, 1.3 µM for isoleucine, 2.5 µM for leucine, 690 nM for valine, 2.7 
µM for taurine, and 6.5 µM for glutamine. Previous studies reported plasma BCAA 
levels to be significantly higher than the determined LODs in both mice and human 
subjects, therefore the separation assay was deemed sufficient for in vivo analysis. A 22 
second temporal response was achieved for the system, a significant improvement over 
previous studies utilizing the current separation assay. This improvement allows for near 
real time analysis of dynamic changes occurring in in vivo amino acid metabolism. 
Microdialysis probe recovery was determined to be 16% for leucine, 18% for valine, 17% 
for alanine, 18% for taurine, and 14% for glutamate. Although the relative recovery 
percentages were not optimal, this only presents a challenge if amino acids are unable to 
be detected in biological dialysate. Given such high concentrations are expected in 
various tissues, it was decided to proceed with in vivo experiments with the current probe 
design, continuing optimization later on if recovery proved insufficient.  
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2.2 Introduction 
Microdialysis sampling is the preferred sampling technique for in vivo 
measurements due to the small probe size yielding minimal disturbances to surrounding 
tissues, continuous monitoring of multiple analytes, and no net loss of surrounding 
fluid.42,43  Microdialysis has been widely employed in neuroscience and pharmacological 
studies.115 Coupling microdialysis probes to an online analytical technique greatly 
improves the temporal resolution of the assay.49 Microdialysis sampling produces low 
mass recovery due to the small sample volumes involved,64 and therefore high-speed CE 
is an excellent analytical separation method for online analysis due to its fast analysis 
time,71,116 low volume requirements and high mass sensitivity.64 
Online coupling of a microdialysis probe to an analytical system is possible due to 
the MWCO of the dialysis membrane acting as a purification step.117 Direct coupling of 
microdialysis probes with high speed CE has been shown previously.71,74,88 Microdialysis 
probes are constructed in-house using a side-by-side geometry as previously reported.101 
Sampling regions of probes varied from 3 mm to 1 cm in length, depending on use for in 
vivo versus in vitro applications. Bioamine derivatization has been optimized to produce 
a 5 minute reaction time with NBDF by heating portions of the reaction capillary.48 High 
speed CE with online microdialysis sampling has been reported to achieve separations in 
under 5 seconds.97 This online technique has been adapted to analyze various 
neurotransmitters in in vivo systems,48,118 as well as online analysis of an astrocyte in 
vitro model.45  
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Microdialysis has been reported in tissues such as the dermis,60,62 tumors,1 
muscle,56 liver,57,58 as well as intravenous sampling.51,52 It has also been used to measure 
analytes such as inflammatory proteins,119 glucose,120 and pyruvate and lactate121 in 
adipose tissue, but time points were only collected on the timescale of minutes to hours. 
A separation assay utilizing α-cyclodextrin was developed and optimized for the in vitro 
analysis of adipocytes.122 BCAAs were resolved and their dynamics were analyzed as 
adipocytes were stimulated with glucose, insulin, and artificial sweeteners. This analysis 
however, was performed offline and had a temporal response of 60 – 90 seconds. 
With the intention to implement this separation assay in an online analysis of 
BCAAs and their related metabolites from adipose tissue and skeletal muscle, 
instrumental parameters had to be examined to test this assay’s suitability for in vivo 
studies. Near real time dynamic information regarding these bioamines is desired, and 
thus the temporal response of the system must be drastically improved. Optimization 
proceeded to improve the temporal resolution of the assay, sacrificing resolution where 
possible. The MD-CE assay was transitioned into an online analysis tool, optimized for 
separations under 20 seconds in adipose tissue and skeletal muscle.  
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2.3 Materials and Methods 
2.3.1 Chemicals and Reagents 
Chemicals. All amino acid standards were purchased from Sigma Aldrich (St. 
Louis, MO). D-glucose was purchased from Gibco (Life Technologies Corp., Grand 
Island, NY) and sodium tetraborate decahydrate was purchased from CHEM-IMPEX 
Int’l Inc. (Wood Dale, IL). 
Buffers and Solutions. All solutions were prepared in deionized (DI) water (Milli-
Q, 18.2 MΩ; Millipore, Bedford, MA) and filtered (0.22 µm). Ringer’s solution was 
prepared with NaCl (123 mM), CaCl2 (1.53 mM), KCl (4.96 mM) and 5 mM glucose 
with pH adjusted to 7.5. Artificial cerebral spinal fluid (aCSF) was comprised of NaCl 
(145 mM), KCl (2.7 mM), MgSO4 (1.0 mM) and CaCl2 (1.2 mM). The conditioning of 
microdialysis probes is the only instance in which aCSF was used during 
experimentation. Sheath flow buffer was comprised of 90 mM borate adjusted to pH 10 
and CE separation buffer contained 90 mM borate/35 mM α-cyclodextrin (food grade, lot 
010760F206, Cyclodextrin Technologies Development Inc., Alachua, FL) adjusted to pH 
10. Derivatization solution was prepared by dissolving 40 mM NBDF (TCI America, 
Portland, OR) in methanol and mixing 1:1 with 500 µM HCl, producing a final 
concentration of 20 mM NBDF/250 µM HCl in 50% methanol. Derivatization solution 
was prepared daily and degassed under vacuum for 2 minutes prior to use. 
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2.3.2 Microdialysis 
Microdialysis probes were constructed in-house using a side-by-side geometry as 
previously reported101 (see Figure 2.1). Two 40 µm i.d. × 105 µm o.d. fused silica 
capillaries (Polymicro Technologies, Phoenix, AZ) were inserted into a 200 µm diameter 
hollow fiber, regenerated cellulose dialysis membrane (13 kD MWCO, Spectrum 
Laboratories, Rancho Dominquez, CA) and off-set by 3 mm to generate a sampling 
region. Capillaries were sealed in place using polyimide resin (Alltech, Deerfield, IL). 
Prior to use probes were conditioned with ethanol (55 µL/h for 25 minutes) followed by 
aCSF (55 µL/h for 25 minutes). During analysis probes were perfused with Ringer’s 
solution at 25 µL/h. 
 
2.3.3 Online CE-LIF Instrumentation 
Online Derivatization. Dialysate was transferred to a 250 µm i.d. stainless steel 
cross (Valco Instruments Co. Inc., Houston, TX) in a 40 µm i.d. × 360 µm o.d. fused 
silica capillary (see Figure 2.1). Borate buffer and derivatization solution were introduced 
at the reaction cross at 5 µL/h each. The derivatization reaction proceeded through a 90 
cm long, 75 µm i.d. × 360 µm o.d. fused silica capillary, of which a 66 cm portion was 
heated to 80 ⁰C, by running the capillary through flexible tubing containing water from a 
heating bath (NESLAB EX-7 Digital One heating bath circulator, Thermo, Newington, 
NH). Capillary dimensions and all flow rates produced a reaction time of 5 minutes. 
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Figure 2.1. Schematic of the high-speed online MD-CE-LIF instrument. Probes are placed into an 
Eppendorf tube containing amino acid standards, and then perfused with Ringer’s solution (A). Perfusate 
(B) mixes with borate buffer and NBDF through a heated reaction capillary prior to injection onto the CE 
separation capillary. A flow gated interface allows for the reaction capillary (C) and separation capillary 
(D) to be coaxially aligned across the separation buffer channel (E-F). 
 
High-Speed CE. Discrete sample plugs from the reaction capillary were injected 
onto a 6.2-6.5 cm long, fused silica CE separation capillary (5 µm i.d. × 360 µm o.d.) 
using a flow gated interface.96 The separation and reaction capillaries were coaxially 
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aligned leaving an approximately 50 µm gap in-between. Separation buffer was pumped 
through this spacing at 40 mL/h using a syringe pump (Pump 22 syringe pump, Harvard 
Apparatus, Holliston, MA). To perform an injection, buffer flow was stopped for 750 ms 
using a pneumatically actuated valve (C2-3000A 10 port valve, Valco Instruments Co. 
Inc., Houston, TX) controlled by an in-house developed LabView program. Following 
this delay, -19 to -21 kV of injection voltage was applied at the outlet of the separation 
capillary for 100 ms. Buffer crossflow was then resumed as the potential was increased to 
the separation voltage (-21 to -23 kV) over a period of 500 ms. 
Detection Scheme. Laser-induced fluorescence (LIF) detection was performed 
using the 488 nm line of a 60 mW diode pumped solid-state laser (Coherent, Santa Clara, 
CA). The laser beam was expanded using a 10× beam expander (Edmund Optics Inc., 
Barrington, NJ) and focused directly beneath the outlet of the separation capillary, in a 
sheath flow cuvette,123 using a 1× lens. A 60×, 0.7 NA long working distance objective 
(Universe Kogaku, Oyster Bay, NY) collected fluorescence at 90⁰. Collected emission 
was passed through spatial (~1 mm) and bandpass filters (543.5 ± 10 nm) and detected 
using a photomultiplier tube (PMT R1477, Hamamatsu Corp., Bridgewater, NJ). Current 
was filtered with a 10 ms rise time, amplified (Keithley Instruments Inc., Cleveland, OH) 
and recorded using a data acquisition card (National Instruments Corp., Austin, TX). 
Data was analyzed using Cutter Analysis 7.0.124  
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2.4 Results and Discussion 
2.4.1 Separation of Standards 
Prior to in vivo experiments, the performance of all instrumental components and 
the separation assay must be assessed. It is imperative that all analytes of interest be 
identified and separated reproducibly in standard solutions. A twenty four amino acid 
mixture was run on the MD-CE instrument to identify analytes and determine 
reproducibility. Addition of 35 mM α-cyclodextrin to the separation buffer (90 mM 
borate, pH = 10) aided in the separation of amine analytes.122 As shown in Figure 2.2, 
fifteen amino acids were able to be separated and identified.  
 
Figure 2.2. Online MD-CE analysis of small molecule amine standards in under 20 seconds. Peaks of 
interest were resolved from other analytes in the separation and identified as (1) arginine, (2) lysine, (3) 
lysine, (4) isoleucine, (5) leucine, (6) methionine, (7) phenylalanine, (8) valine, (9) GABA, (10) glutamine, 
(11) alanine, (12) DL-β-amino-n-butyric-acid (β-ABA), (13) glycine, (14) taurine, (15) glutamate and (16) 
D/L aspartate. 
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The separated standard mixture contained twenty four acids: D/L serine, L 
alanine, L tyrosine, L tryptophan, D asparagine, L arginine, L histidine, D/L aspartic acid, 
L leucine, D/L-β-amino-n-butyric-acid (β-ABA), L methionine, L glutamic acid, L 
valine, L cysteine, β alanine, L isoleucine, glycine, L glutamine, L phenylalanine, L 
citrulle, L threonine, taurine, γ-amino-n-butyric-acid (GABA), and L lysine. As shown 
above, sixteen peaks corresponding to fifteen different amino acids, were able to be 
identified in the separation window. The remaining amino acids were assumed to co-elute 
with the NBD-OH peak. This conclusion was reached after each amino acid was tested 
individually to determine migration times. NBD-OH is a byproduct of the NBDF 
derivatization reaction, which is currently unable to be eliminated. Adjustments to pH 
and borate concentration can be used to shift the NBD-OH peak in the electropherogram, 
to minimally interfere with analytes of interest. All amino acids of interest, BCAAs and 
downstream metabolites (alanine, glutamate, and glutamine), are able to be separated and 
identified with the described separation assay, and therefore the location of the NBD-OH 
peak was suitable for further experimentation. 
Reproducibility of the separation is imperative for a lengthy period of time, as in 
vivo experiments are expected to proceed longer than one hour. Figure 2.3 displays full 
amino acid standard separations, with overlaid electropherograms collected at various 
time points during an hour long experiment. As shown, all fifteen amino acids are present 
with the same signal intensity and no peak drifting for the entire length of time. Therefore 
the separation was deemed reproducible. 
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Figure 2.3. Overlaid electropherograms from a twenty four amino acid standard separation. 
Reproducibility of separation was able to be verified for an hour of instrument operation. 
 
All amino acids were separated in under 15 seconds, a dramatic improvement in 
the resolution of the same separation assay in an offline MD-CE system. Improving the 
speed of separations was critical in this online MD-CE instrumentation, as it determined 
the temporal resolution of the assay. A modest reduction in the resolution of several 
amino acids occurred due to this temporal response decrease, however all analytes of 
interest can still be identified and separated from one another. This improvement in 
analysis time will be significantly beneficial for future dynamic in vivo experiments. A 
theoretical plate count was calculated to be 51,000 for this instrument.  
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2.4.2 Limits of Detection 
It is crucial that the online MD-CE assay be capable of detecting biological 
concentrations of amino acids present in adipose tissue and skeletal muscle. Blomstrand 
et al. monitored the effects of amino acid supplements and exercise on plasma BCAA 
levels. Isoleucine levels ranged from 77 to 90 µM, leucine levels ranged from 150 to 188 
µM, and valine spanned 298 to 330 µM.125 Marchianti et al. examined plasma 
concentrations of amino acids in wild type and db mice, an animal model for type 2 
diabetes. Isoleucine concentrations ranged from 74 to 219 µM, depending on 
experimental conditions. Leucine concentrations ranged from 109 to 349 µM and valine 
concentrations spanned 213 to 508 µM.126 The LODs for the described assay were 
determined by 3 standard deviations above baseline noise. These LODs represent the 
concentration of analytes outside the microdialysis probe, prior to the labeling reaction. 
LODs for the online MD-CE assay were estimated to be 1.7 µM for glutamate, 1.3 µM 
for isoleucine, 2.5 µM for leucine, 690 nM for valine, 2.7 µM for taurine, and 6.5 µM for 
glutamine. Low concentrations of amino acids were measured in order to confirm the 
system’s ability to detect small amounts of analyte. As demonstrated in Figure 2.4, 
concentrations as low as 5 µM are easily distinguished from baseline. In conjunction with 
the plasma concentrations of BCAAs from Marchianti and Blomstrand, this suggests that 
detection of BCAAs in adipose tissue and skeletal muscle using this assay will not be an 
issue. 
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Figure 2.4. LOD studies using the online MD-CE system. Electropherograms from BCAA standards of 
varying concentrations. Peaks identified as (1) isoleucine, (2) leucine, (3) valine, (4) glutamine/alanine and 
(5) glutamate.  
 
2.4.3 Temporal Resolution 
 Stimuli will be administered to adipose tissue and skeletal muscle in vivo with the 
goal to monitor changing amino acid levels. The temporal response of the assay must be 
as close to near real time as possible, in order to observe these changes as they are 
occurring. In order to assess the temporal response of the MD-CE assay, standards of 
varying leucine concentration were prepared. The microdialysis probe was transferred to 
a leucine standard for five minutes, then transferred to a blank Ringer’s solution for three 
minutes, to a different leucine concentration for another five minutes, and then back to 
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blank Ringer’s solution. This process was repeated for all concentrations of leucine 
standard, as shown in Figure 2.5. 
 
Figure 2.5. The temporal response of the online MD-CE assay. Probes were transferred from solutions of 
different concentrations of leucine, being placed in a solution of Ringer’s (blank) in between each transfer. 
A full signal is achieved within 1-2 separations, yielding a temporal response of 22 seconds. 
 
 As demonstrated above, the signal for leucine plateaued within 1-2 separations, 
indicating a 22 second temporal resolution is achieved. Separation time is 20 seconds for 
each run, however factors such as injection and delay time also contribute to the overall 
temporal response of the system. A 22 second temporal resolution is a significant 
improvement over the 60-90 second temporal resolution of the previous offline MD-CE 
assay for BCAAs.122 Hence, the modest sacrifice in resolution of amino acids serves to 
transform the MD-CE assay into a near real time method. The run to run reproducibility 
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was 8%, as determined by relative standard deviation. Analogous to LOD calculations, 
biological changes greater than 24% (i.e. 3 × rsd) can be observed with statistical 
significance.  
 
2.4.4 Microdialysis Probe Recovery  
 One of the fundamental limitations of microdialysis sampling is that the fraction 
of analyte recovered in the dialysate is always less than the actual concentrations of 
analyte in the surrounding matrix about the probe. The ratio of these two concentrations 
is known as relative recovery. Relative recovery is affected by the size of the probe’s 
sampling region, probe membrane material, and flow rate of the perfusate. Previous in 
vitro work utilized a sampling region of 1 cm, to maximize exposure to various cell 
models,45,46 while previous in vivo studies employed a 3 mm sampling region to minimize 
damage to surrounding tissue upon probe implantation and more accurately target 
specific tissue locations.48,101 Probe sampling regions were set at 3 mm for all described 
experiments and regenerated cellulose was chosen as the dialysis membrane material due 
to its successful use in the previous biological studies. 
 As perfusion rates into the probe increase, relative recovery of analytes is 
decreased; therefore slow perfusion rates are preferred, particularly in vivo. Perfusion 
rates were set at 25 µL/hr, which was optimized with the NBDF derivatization reaction to 
yield a complete labeling reaction within 5 minutes. Relative recovery of microdialysis 
probes constructed in house was determined to be 16.2% for leucine, 18.2% for valine, 
17.1% for alanine, 17.8% for taurine, and 13.5% for glutamate. Probes constructed on 
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various days and from different batches were tested, and their results averaged, to 
determine a representative recovery across all probes utilized. All analytes displayed 
similar recoveries, which was encouraging as it demonstrates that no one analyte diffuses 
more favorably across the dialysis membrane as compared to others. Although the 
recovery percentages are not optimal, the only requirement is that amino acids levels are 
able to be detected in vivo, with dynamic changes observed in near real time. 
Experiments proceeded towards in vivo studies, with adjustments to perfusion flow rate 
and/or sampling region size kept as options for future optimization should probe recovery 
prove to be an issue in vivo.  
 
2.5 Conclusions 
We have developed an analytical platform to analyze the in vivo dynamics of 
BCAAs and related metabolites within adipose tissue and skeletal muscle. BCAAs and 
related metabolites were separated and identified to test the separation assay’s 
performance, with LODs determined to be suitable for expected biological 
concentrations. The MD-CE assay achieves a 22 second temporal resolution, making this 
system a near real time analysis method for small molecule bioamine dynamics. Future 
studies will focus on applying a variety of stimulations to adipose tissue both locally and 
systemically. It is our goal through these experiments, to determine the full role BCAAs 
play in overall body metabolism.  
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Chapter 3 
Design and Development of an In Vivo Protocol for the 
Sampling of Adipose and Skeletal Muscle Tissue 
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3.1 Summary 
 In this work, an in vivo protocol was designed, developed and subsequently 
approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Minnesota. The protocol was designed to be comprehensive, allowing for 
multiple generations of research to complete a full scale study of BCAA metabolism in 
adipose tissue and skeletal muscle induced by various stimuli. 
 The animal model selected was C57BL6 male mice, due to their frequent use in 
obesity research. Sampling locations were chosen based on their involvement in 
metabolically-related functions and providing an easily accessible site for microdialysis 
probe insertion. Therefore the quadriceps of the hind limb and the inguinal adipose tissue 
depot were selected for skeletal muscle and adipose tissue. Anesthetic regimes and 
euthanasia methods were designed based on available equipment, personnel safety, and 
safety and ease for the animal model. Isoflurane anesthesia is the chosen technique, with 
initial induction allowing mice to remain free-moving in an induction chamber, and 
maintenance of surgical levels occurring via a nose cone in close proximity to the high 
speed MD-CE instrument. An intracardiac shot of potassium chloride (KCl) under 
increased isoflurane was chosen as the prominent euthanasia method, with a thoracotomy 
utilized as a secondary verification procedure. Stimuli chosen for administration included 
insulin, glucose, BCAAs, and twelve artificial sweeteners.  
 Finally, a detailed standard operating procedure (SOP) is provided. Much of the 
animal handling protocol was designed through practical experience, and thus should be 
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provided to the next generation of research to aide in their in vivo experimentation 
progress.  
 
3.2 In Vivo Protocol Design 
3.2.1 Model and Tissue Selection 
 The aim of the proposed research is to study the induced metabolism of 
bioamines, particularly BCAAs, by various stimuli in vivo. Adipose tissue and skeletal 
muscle are the desired sampling locations, as it has been shown that adipose tissue plays 
a significant role in regulating BCAAs30,31 and skeletal muscle plays an important role in 
overall body metabolism.3 With this research providing key insights into the metabolism 
dynamics of adipose tissue under various metabolic conditions, an animal model that will 
allow for comparisons to current metabolism and obesity literature is desired. 
 C57BL6 male mice were chosen as the animal model due to their frequent use in 
obesity research.127,128 This strain of mouse is the most commonly used inbred strain,129 
and the progression of their metabolism dysfunction mimics that of the progression of 
human obesity.41 Male mice will be used exclusively to avoid unintended pregnancies in 
females, and most importantly, to avoid the complications caused by the presence of 
mammary tissue. Female mice have five pairs of mammary glands, all situated within 
adipose tissue depots (See Figure 3.1).130,131 Once fully developed, mammary tissue can 
extend through almost all of the subcutaneous areas,132 therefore probe insertion into 
solely adipose tissue would be extremely challenging.  
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Figure 3.1. Locations of mammary glands in a female mouse.  
  
Metabolic research frequently targets adipose tissue in the epididymal, 
subscapular, and inguinal depots (See Figure 3.2).133 The epididymal depot is located 
deep in the abdominal cavity, attached to the testes and epididymis. Microdialysis probes 
will be inserted into the desired tissue for sampling, with as minimal disturbances to the 
surrounding tissue as possible. The location of epididymal adipose tissue causes 
reproducible probe implantation with minimal damage to be extremely difficult. The 
subscapular adipose tissue depot is located between the scapulae, underneath the 
subcutaneous layer. This depot contains BAT however, which is primarily involved in 
thermogenesis.134 Since the described research is focused on BCAA regulation and 
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metabolic function, WAT is required. Therefore all adipose tissue sampling will occur in 
the inguinal adipose tissue depot, located in the joint region where the hind limb attaches 
to the abdomen. Its subcutaneous nature will allow for microdialysis probe insertion with 
minimal damage to both surrounding tissues and the probe itself.  
 
Figure 3.2. Adipose tissue depots in a mouse. The inguinal depot selected for sampling is highlighted.  
 
The skeletal muscle location chosen for sampling was the quadriceps of the hind 
limb (See Figure 3.3).135 The quadriceps were selected due to their ease of accessibility, 
particularly in regards to the orientation of the mouse during anesthesia. The mouse must 
be positioned on its back in order to access the inguinal adipose tissue depot with a 
microdialysis probe, making the quadriceps also easily accessible. This selection allows 
for dialysate collection to proceed from both tissue locations in the same mouse, if 
simultaneous samples from various locations were ever desired. 
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Figure 3.3. Skeletal muscle locations in a mouse hind limb, with the sampling location highlighted. 
 
3.2.2 Anesthesia 
 Mice must be anesthetized throughout the procedure, prior to microdialysis probe 
insertion and through the entirety of all data collection. Anesthetic regimes can utilize 
either injectable or inhalant anesthetics, with inhalant methods offering the advantages of 
rapid recovery, a more steady-state dosing, and quick adjustment of anesthetic 
concentration based on the animal’s needs.136 This allows for a more steady anesthetic 
depth throughout the entire experiment. Inhalation anesthesia has also been shown to 
have a reduced effect on kidney and liver functions in mice, as well as causes less 
cardiovascular depression. Disadvantages of inhalant methods include hypotension, 
vasodilation, myocardial depression and respiratory depression.137  
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 Common inhalant anesthetics include nitrous oxide, methoxyflurane, halothane, 
sevoflurane, and isoflurane. Nitrous oxide displays positive analgesic properties, however 
its use as the only source of anesthesia in rodents is discouraged as it is not a complete 
anesthetic.138 Methoxyflurane releases inorganic fluoride ion once metabolized, which 
causes renal damage. Therefore an elaborate scavenging system is recommended for 
personnel safety.139 Halothane has demonstrated hepatotoxic and mutagenic effects in 
humans following repeated exposure, and sevoflurane is often cost prohibitive for use in 
animal studies.137 Isoflurane is the recommended anesthetic for Swiss, CD-1, and 
C57BL6 mice strains,140 and it exhibits rapid induction and recovery times. 
Disadvantages include delayed growth and cleft palates in newborns with mothers 
exposed to isoflurane and decreased immune systems.141,142 
 C57BL6 male mice are initially induced using an induction chamber. An 
induction chamber is utilized in order to minimize stress on the animal prior to 
anesthesia. Physical restraint of mice can cause increases to epinephrine and 
corticosteroid levels, increase to glucose levels, and stimulate respiratory and 
cardiovascular functioning.143 By allowing mice to be free-moving during initial 
induction, stress from the animal can be minimized. Induction levels in mice using 
isoflurane are recommended to be 3.5 - 4.5% according to Flecknell144 and 4 – 5% in 0.8 
– 1.0 L/min according to Gargiulo.137 The approved IACUC protocol allows for a range 
of 0.5 – 5.0% isoflurane in 1 L/min oxygen, adjusting based on each individual mouse’s 
response. Prior to anesthetic induction, all mice experience a four hour daytime fast. Brief 
fasting prior to anesthesia has been shown to help normalize animal to animal variability 
42 
 
in several imaging studies.143 Daytime fasting, while still allowing free access to water, is 
anticipated to help normalize glucose and insulin levels across mice. 
 Post induction, mice are transferred to a nose cone situated on top of a heating 
pad. Hypothermia in mice is one of the most common causes of anesthetic death136 and 
the core body temperature of a mouse will begin to rapidly diminish immediately 
following induction.137 The heating pad, and occasional use of a warm blanket, are 
utilized as necessary in order to maintain an acceptable core body temperature. Isoflurane 
is delivered in 1 L/min oxygen at the nose cone at a concentration of 0.5 – 2.5%, 
depending on individual mouse reflexes. Recommended dosages of isoflurane for 
surgical maintenance range from 1 - 3% in 0.8 – 1.0 L/min.136,137 Anesthetic depth is 
continuously verified during the experiment by testing pedal, hind-limb and tail-pinch 
reflexes. Isoflurane concentration is adjusted as necessary to ensure proper anesthetic 
depth. Ophthalmic ointment is also applied to the eyes during maintenance of surgical 
anesthesia levels to prevent corneal desiccation.137  
 
3.2.3 Microdialysis Probe Insertion and Stimuli Administration 
 BCAA metabolism will be monitored in adipose tissue and skeletal muscle as it is 
induced by various stimuli. BCAAs regulate protein synthesis,12 insulin sensitivity,21,28 
insulin secretion,10 and appetite control.11 It has also been shown that circulating levels of 
BCAAs are elevated in obese patients and those with type 2 diabetes,21,26-28 and that these 
circulating levels deceased upon weight loss. This demonstrates adipose tissue’s role in 
regulating BCAA concentrations.20,30,31 Recent studies have also shown that artificial 
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sweeteners alter the gut microbiota of mice,145 prompting the need for further analysis of 
artificial sweeteners, and their potential effects on BCAA metabolism. 
 It was desired that the IACUC protocol be designed to allow for a full scale study 
into the metabolism dynamics of BCAAs over multiple generations of research. 
Bioamine levels were to be monitored in the inguinal adipose tissue depot and the hind 
limb quadriceps of mice. Microdialysis probes were the sampling method chosen, and it 
was determined that they would be inserted into the tissue of interest through the use of a 
hollow needle. The preliminary design hypothesized that the microdialysis probe would 
be threaded through a hollow needle, and once flush with the outlet tip, both the needle 
and microdialysis probe would be inserted into the tissue. The needle would then be 
pulled back over the probe, leaving the probe in place in the tissue of interest. The 
proposed implantation procedure prevents damage to the probe membrane, and is 
theoretically feasible for both types of tissue. Hands-on experimentation will confirm this 
method’s viability. 
 As a comprehensive study examining adipose tissue’s role on BCAA metabolism, 
multiple dosing methods were desired. Stimuli were to be administered via reverse 
microdialysis, such that only the tissue of interest would be initially exposed to the 
stimuli. In this way, the sole response of the tissue could be examined. Systemic methods 
of tail vein injection and oral gavage were also to be administered so that the stimuli 
would be carried through the bloodstream and adsorbed through the gastrointestinal tract, 
respectively, prior to affecting the tissue of interest. In this way, the tissue’s response of 
BCAA metabolism will be captured after it has been affected by the stimuli and all 
interworking bodily systems. 
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 Stimuli to be studied include glucose, insulin, BCAAs and twelve artificial 
sweeteners. The artificial sweeteners include stevioside, steviol, sucralose, aspartame, 
saccharin, acesulfame K (ace K), sucrose, fructose, aspartate, phenylalanine, neotame, 
and neotame de-ester. While saccharin, sucralose, aspartame, ace K, and neotame are 
recognized as commercially available artificial sweeteners,146,147 the other metabolites are 
included in order to analyze all components possible post-digestion. Aspartate and 
phenylalanine are the resulting compounds once aspartame has been digested,148,149 and 
glucose and fructose result from sucrose’s metabolism. Neotame undergoes a de-
esterification process to form neotame de-ester,150 and stevioside is metabolized to 
steviol.151 Insulin and BCAAs will also be examined as interesting components related to 
overall body metabolism. Maximum concentrations of each stimuli were set as twice the 
acceptable daily intake (ADI) for each metabolite,152-161 with multiple concentrations of 
each metabolite expected to be provided to tissues in order to yield pharmacological 
kinetics. Maximum concentrations for each stimuli in the protocol are listed as: 10 mg/kg 
stevioside, 8 mg/kg steviol, 10 mg/kg sucralose, 100 mg/kg aspartame, 10 mg/kg 
saccharin, 30 mg/kg ace K, 2 g/kg glucose, 2 g/kg fructose, 2 g/kg sucrose, 100 mg/kg 
aspartate, 100 mg/kg phenylalanine, 4 mg/kg neotame, 4 mg/kg neotame de-ester, 2 U/kg 
insulin, 140 mg/kg valine, 260 mg/kg leucine, and 120 mg/kg isoleucine.  
 
3.2.4 Euthanasia 
 Following each experiment, mice must be euthanized due to risk of infection. All 
experiments, anesthesia, and probe implantation occur in the laboratory of Dr. Michael 
Bowser, and while associated benchtops and instruments are routinely cleaned and 
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sterilized, other areas in the laboratory following non-sterile protocols increase the risk of 
post-surgery infection. Euthanasia methods are chosen based on their reliability, ability to 
be painless, irreversibility, yielding rapid unconsciousness, and safety and ease of 
personnel to perform.162 The absence of respiratory function and heartbeat are good 
indicators of a complete euthanasia procedure. It is often recommended however, that a 
verification procedure be performed after confirmed death, such as exsanguination or a 
thoracotomy.163  
 Recommended euthanasia methods for small rodents include, but are not limited 
to, barbiturates, carbon dioxide, potassium chloride, decapitation, and cervical 
dislocation. Barbiturates, such as sodium pentobarbital, are delivered intravenously and 
are considered both safe and humane. They are one of the more common euthanasia 
methods employed,164 but their storage and use in a laboratory requires a DEA license to 
be held and maintained by all relevant personnel. Carbon dioxide is another commonly 
used euthanasia technique, particularly for laboratories euthanizing multiple rodents at 
once. Death occurs within 5-6 minutes,164 however the University of Minnesota’s IACUC 
and Research Animal Resources (RAR) staff require a secondary procedure, such as 
cervical dislocation, for complete verification. KCl euthanasia is performed by 
administering an intracardiac dose of 1-2 mEq/kg. This procedure must be performed 
while the animal is still under anesthesia. Decapitation utilizes a guillotine to sever the 
rodent’s head from the body at the atlanto-occipital joint. This procedure is most 
commonly employed in pharmacological studies when the histology of brain slices are 
desired. Finally, cervical dislocation separates the skull and spinal cord by applying 
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pressure to the base of the skull while simultaneously pulling on the tail.164 This 
technique can only be performed in small rodents. 
 Due to the extra complications introduced by the requirement of a DEA license, 
and the lack of need for brain slices and risk to personnel safety through guillotine 
operation, barbiturates and decapitation are not utilized in the described protocol. Carbon 
dioxide, while commonly employed, would require the purchasing of carbon dioxide 
tanks and euthanasia chamber. Since only one animal is used for each experiment, the 
benefit of being able to euthanize multiple mice simultaneously does not offset the 
purchasing of new equipment. Cervical dislocation is arguably the most advantageous 
method, requiring no purchased equipment and feasible when experimenting with only 
one mouse at a time, however personnel ease and comfort at performing the technique 
did not make this a desirable method. Personnel have been trained on proper cervical 
dislocation techniques, in the event an emergency required its use, but the euthanasia 
method chosen for the described protocol is an intracardiac dose of KCl under anesthesia, 
followed by a thoracotomy. 
 At the conclusion of each experiment, isoflurane is increased to 5.0% in 1 L/min 
oxygen at the nose cone for a minimum of 3 minutes. KCl (1 – 3 mEq/kg) is prepared in 
0.5 mL DI water. The KCl solution is delivered through an intracardiac shot with a 1 mL 
syringe, and death is confirmed by the cessation of heartbeat and respiratory function. 
Following death confirmation, the mouse is removed from the nose cone and a 
thoracotomy is preformed to create a pneumothorax as a secondary procedure.  
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3.3 Standard Operating Procedure 
 Currently I am the sole researcher trained and practiced in all animal handling and 
in vivo experimental procedures. A portion of my research responsibility during graduate 
school was to design and establish a functioning in vivo protocol that would allow for 
experimentation for an extended period of time. The protocol designed, submitted and 
approved by IACUC is valid until February 2019, and thus there is a high probability that 
a future student will engage in in vivo experiments after my departure. This section serves 
as my attempt to pass along the practical knowledge and experience I have gained over 
the last several years. It is my hope that the next researcher will be able to continue where 
I left off, and utilize the preliminary work completed. 
 
3.3.1 Picking up Mice 
 Mice are housed by RAR in Jackson Hall. RAR veterinary staff will accept 
animal deliveries, feed mice, and clean the cage bedding for a daily fee. Housing is 
located in a Specific Pathogen Free (SPF) zone and therefore all personnel entering 
animal housing must have completed microisolator training and follow all protocols 
described therein. Bring a black cloth to the facilities so the cage can be covered when 
traveling back to Nils Hasselmo (cage covering is required when transporting animals so 
the contents of the cage remain unknown in public). In the Jackson Hall facilities, retrieve 
a pink carcass bag from the supply closet. These will be needed to return all animal waste 
at the conclusion of the experiment.  
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 Retrieve the animal cage containing a single mouse. Mice are housed individually 
so only the animal to be used for an experiment leaves the SPF facilities. Cover the cage 
with the black cloth and use the underground tunnels and skyways free from students to 
transport the cage back to the laboratory, avoiding class pass-periods whenever possible. 
Once back in the laboratory, remove the cover from the cage. If the experiment calls for a 
4 hour daytime fast, remove the food from the cage but leave the mouse free access to 
water. 
 
3.3.2 Initial Induction of Anesthesia 
 The anesthesia equipment utilized for experiments includes an isoflurane 
vaporizer, switching manifold, nose cone, oxygen tank, induction chamber and waste 
scavenging pump. The isoflurane vaporizer must be calibrated annually as per IACUC 
instructions. Prior to each experiment, ensure the vaporizer is filled with isoflurane. See 
Figure 3.4 for vaporizer details. 
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Figure 3.4. Isoflurane vaporizer schematic. Oxygen lines attach to vaporizer at (1) and the oxygen rate 
during anesthesia is adjusted at (2). Isoflurane is refilled through the chamber at (3), with a full tank being 
denoted by the liquid level reaching the line at (4). The tank must never be allowed to drop below the line 
denotation at (5). Isoflurane concentration is adjusted at (6) and the isoflurane gas lines attach at (7) to 
deliver anesthesia gas to the switching manifold. 
 
 Attach the gas anesthetic waste line to the scavenging pump (located in the fume 
hood). Make sure all gas lines to the oxygen tank, vaporizer, induction chamber, and nose 
cone are securely fastened. Above the nose cone there is a scavenging line venting 
system; open the scavenging line and turn on the heating pad prior to initial induction 
(heating pad is usually set at 50-75% power to begin; adjust as necessary throughout the 
experiment). Transfer the mouse from the cage to the induction chamber. Techniques to 
pick up and maneuver mice are taught in the Mouse Basics class, hosted through RAR. 
Once the mouse is placed gently inside the induction chamber, place the lid on the 
chamber and pull the fume hood sash down (as the induction chamber waste gas vents 
into the fume hood). Switch the manifold to select only the induction chamber. 
O
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Isoflurane 
Vaporizer 
1.  
2.  3.  
4.  5.  
6.  
7.  
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 Open the oxygen tank and set the regulator to 40 psi. Turn on the oxygen supply 
at the vaporizer to be 1 L/min and turn on the isoflurane supply. The protocol approved 
by IACUC allows for 0.5-5.0% isoflurane during induction, however 5.0% has been the 
concentration most frequently used. Within one minute, the mouse should begin to 
experience the anesthetic. Typical responses include curious smelling and increased 
movement around the chamber. Mice (20-25g, 6-8 weeks of age) are usually under an 
appropriate depth of anesthesia to be transferred to the nose cone in 6 minutes (changes 
in breathing rate are the visual indicators of deep anesthesia). 
 Once the mouse is at the correct depth of anesthesia for transfer, turn down the 
isoflurane to 2.5% (current protocol allows for 0.5-2.5% isoflurane at nose cone). Adjust 
the manifold: induction chamber valve – OFF, nose cone valve – ON, waste line valve – 
ON. Remove the lid from the induction chamber and transfer the mouse to the nose cone. 
Pull the fume hood sash back down when finished, as the waste line from the nose cone 
vents into the hood. 
 
3.3.3 Anesthetic at Nose Cone 
 Place the nose of the mouse firmly inside the nose cone, holding in this position 
for several moments, to ensure depth of anesthesia is still sufficient. After several 
minutes, remove the mouse from the nose cone and quickly apply ophthalmic eye cream 
using a cotton swab. Immediately place the mouse back into the nose cone, positioned on 
its back with its nose firmly in the nose cone. Adjust the nose cone height to allow for 
comfortable positioning of mouse (neck should be aligned straight with body and not 
bent back). Perform pedal, hind limb and tail reflex testing. Pedal reflex testing involves 
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pinching between the toes, hind limb reflex testing pinches the limb above where the foot 
attaches, and tail reflex testing pinches the tail just below where it attaches to the body. 
Pinch firmly, and if the mouse is under sufficient levels of anesthesia, no twitching or 
movement will be observed in either hind limb or the tail. If no responses are observed, 
secure the mouse to the heating pad to avoid movement of any tissue during the 
experiment. If responses are present, adjust the isoflurane until no reflexes are observed. 
 Reflex testing must be performed and recorded every 5-15 minutes to ensure 
anesthetic depth is sufficiently maintained. Ideally, the isoflurane concentration will be 
just enough to maintain anesthesia, and no more. Typically the nose cone is set at 2.5% 
for the initial transfer, and then reduced to 2.0-2.25% for the remainder of the 
experiment, depending on the reflex responses of individual mice. Throughout the 
experiment, the temperature of the mouse must be carefully monitored as well. Mice are 
extremely susceptible to hypothermia under anesthesia, and therefore if the limbs ever 
feel cool, increase the heating pad power. Be careful not to overheat the mouse. Once 
anesthetic depth has been successfully maintained at the nose cone for approximately 30 
minutes, the microdialysis probe can be inserted into the tissue of interest. 
 
3.3.4 Microdialysis Probe Insertion 
 Microdialysis probes should already be connected to the instrument and sampling 
from Eppendorf tubes containing standards in Ringer’s solution. Remove the 
microdialysis probe from the sample vial and thread it through a 19 gauge needle. Be sure 
to thread the probe without bending or damaging the membrane of the sampling region. 
The probe tip should be slightly less than flush with the end of the needle. Push the 
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needle into the tissue of interest, and once at the desired depth, hold the capillary in place 
and pull the needle back over the probe. The microdialysis probe should have remained 
in the tissue, however slight adjustments to its depth can be achieved by grasping the 
probe close to the tissue with tweezers and pulling the probe either further in or out. The 
precise implantation procedure for inguinal adipose tissue and quadriceps muscle is 
described in Chapter 4, however this general procedure can be adapted to most sampling 
locations. In the instance of hind limb or inguinal adipose tissue sampling, once the probe 
is implanted, secure the limb and needle in place to prevent any movement during data 
collection. 
 
3.3.5 Euthanasia 
 Once the experiment is complete, detach the capillary connecting the reaction tee 
to the microdialysis probe. The probe should remain in the tissue for verification of 
location during dissection, however the mouse must be disconnected from the instrument 
for euthanasia. Increase the isoflurane to 5.0% for approximately 3 minutes and then 
deliver an intracardiac shot of KCl. The KCl solution should be previously prepared at 3 
mEq and contained in a 1 mL syringe.  
 To find the heart, place an index finger and thumb on opposite sides of the 
thoracic cavity and move up or down along the cavity until the heartbeat is felt between 
the fingers. Mice have an extremely fast heartbeat, so do not confuse feeling your own 
heartbeat between your fingers with theirs. Once the lateral position of the heart has been 
located, insert the needle into the center of the thoracic cavity at this location, being sure 
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to go underneath the sternum (the needle may need to be inserted at a slight angle). Push 
the KCl solution into the heart slowly. Breathing and heartbeat should cease immediately. 
 Turn off the isoflurane and oxygen at the vaporizer. Remove the deceased mouse 
from the nose cone and place on the bench to perform a thoracotomy. Insert scalpel into 
chest cavity and create an incision opening the chest. This creates a pneumothorax and is 
a confirmation of the euthanasia procedure. Post thoracotomy, dissect the tissue 
surrounding the probe to ensure successful implantation of probe into the desired 
sampling region. For sampling from the inguinal adipose tissue depot or the hind limb 
muscle, dissections typically begin in the upper abdominal region. Using a scalpel and 
scissors, the subcutaneous layer can be separated from the abdominal cavity, without 
puncturing through the abdominal wall. The subcutaneous layer is then carefully 
separated all the way down to the hind limb. Here the inguinal adipose tissue depot can 
be separated from the underlying muscle tissue to verify probe location. After visually 
confirming the microdialysis probe placement, remove the probe from the tissue and 
weigh the mouse for records. 
 
3.3.6 Returning Animal Waste and Cleaning 
 Place the carcass into the pink waste bag. If any paper based materials were 
contaminated with blood (paper towels, cotton swabs, etc.), they will need to be taken 
separately to RAR and disposed of in the proper containers. Cover the cage and pink bag 
with the black cloth and return to Jackson Hall using the tunnels/skyways avoiding 
student traffic. Place the pink carcass bag into RAR’s animal waste fridge and place the 
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cage on the shelves designated for dirty cages. Turn in the white card located on the front 
of the animal cage to the outbox at the entrance to the facilities. 
 All needles, syringes and scalpels used during the experiment should be disposed 
of in the proper sharps container. All capillary, including the microdialysis probe, should 
be disposed of in the proper broken glass container. The heating pad, benchtop, and 
surgical scissors and scalpel (non-disposable) must be sterilized with 70% ethanol. Set all 
valves to OFF in the manifold and verify that the isoflurane and oxygen in the vaporizer 
are turned off. Close the oxygen tank, turn off the heating pad, and close the scavenging 
vent line. Disconnect the scavenging gas waste line from the scavenging pump and store 
all gas lines appropriately.  
 
3.4 Conclusion 
 This work allows for in vivo experimentation within Dr. Michael Bowser’s lab 
through February 2019. Full anesthetic and euthanasia regimes are permitted to be 
conducted within the lab, alongside microdialysis probe implantation procedures. Male 
C57BL6 mice undergo isoflurane anesthesia prior to microdialysis probe implantation in 
either the inguinal adipose tissue depot or the hind limb quadriceps. Tissue is stimulated 
through reverse microdialysis, tail vein injection, or oral gavage by insulin, glucose, 
BCAAs, or a variety of artificial sweeteners. Risk of infection requires this procedure be 
non-survival, and thus an intracardiac dose of KCl followed by a thoracotomy is 
performed for euthanasia. Full procedural details are outlined for future in vivo 
experiments.  
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Chapter 4 
In Vivo Monitoring of Amino Acid Biomarkers from Inguinal 
Adipose Tissue and Skeletal Muscle Using Online 
Microdialysis-Capillary Electrophoresis 
 
 
 
Sections adapted from: 
 “Weisenberger, M.M and Bowser, M.T. Anal. Chem. 2017, 89 (1), 1009-1014.” 
Reproduced with permission 
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4.1 Summary 
 In this work, sampling procedures were developed and optimized for a C57BL6 
mouse. Microdialysis probes were successfully implanted into inguinal adipose tissue 
reproducibly. Placement of the probe was visually verified following each experiment 
with a full dissection. Measurements made in the adipose tissue of four mice generated 
similar basal recordings, including the presence of arginine, lysine, isoleucine, leucine, 
methionine, phenylalanine, valine, GABA, glutamine, alanine, glycine, and taurine. A 
successful and reproducible implantation procedure was also developed for quadriceps 
skeletal muscle, with placement visually verified as well. Basal recordings in muscle 
across three mice found similar traces, with arginine, lysine, isoleucine, leucine, 
methionine, phenylalanine, valine, GABA, glutamine, alanine, glycine, taurine, and 
glutamate detected. 
 To demonstrate the high speed microdialysis-CE assay’s ability to monitor 
metabolism dynamics in near real time, a tail vein stimulation of insulin was 
administered. Bioamine levels were recorded in inguinal adipose tissue prior to, during, 
and post stimulation. Valine, alanine, and taurine levels all drastically increased 
following the initial stimulus, and their levels remained elevated post stimulation. Valine 
levels increased 40% initially before returning to an elevated baseline of 34%. Alanine 
increased by 46% with an elevated baseline of 16%, while taurine increased by 37% with 
an elevated baseline of 21%. All post stimulation levels were found to be significantly 
different than original basal levels (p < 0.001).  It can therefore be determined that the 
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developed assay has the ability to monitor dynamics as they occur in near real time as a 
response to administered stimuli.  
 
4.2 Introduction 
 Current metabolism and obesity research utilizes in vitro, in vivo, and ex vivo 
models, however in vivo experiments allow for interworking body systems to be 
examined. This is an important aspect for metabolism research, given that metabolic 
dynamics occurring in adipose tissue are part of a signaling network that includes the 
pancreas, liver, muscle, and brain.10-12 Current studies are limited in their time response, 
with typical measurements occurring on the timescale of minutes to hours.119-121 The 
developed online high-speed MD-CE assay has a temporal resolution of 22 seconds, 
allowing for near real time measurements of metabolism dynamics. 
 Microdialysis probes have been successfully implanted in the dermis,60-62 liver,57-
59 muscle,54,56 tumor,54,55 and brain50 tissues. In order to record metabolic dynamics in 
near real time, microdialysis probes must be implanted directly into adipose tissue and 
skeletal muscle. This will allow for bioamine levels to be monitored prior to, during, and 
post stimulus administration. Implantation procedures must allow for reproducible 
implantation directly into the tissue of interest, with minimal damage to the surrounding 
tissues and no damage to the probe membrane.  
 C57BL6 mice have been selected as the model for in vivo experiments due to the 
progression of their metabolic dysregulation mimicking that of human’s metabolic 
dyregulation.41 The inguinal adipose tissue was selected as the adipose sampling depot 
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due to its composition of white adipose tissue and its subcutaneous location allowing for 
easier probe insertion.133,134 The quadriceps skeletal muscle was selected as the sampling 
location for muscle due to ease of insertion with the mouse positioning under 
anesethesia.135 Reproducibility between mice for adipose tissue and skeletal muscle 
amino acid signatures will also need to be established in order to draw general 
conclusions regarding induced metabolism dynamics due to administered stimuli.  
 
4.3 Materials and Methods 
4.3.1 Chemicals and Reagents 
Chemicals. Insulin (human recombinant, lot 15L255-B) and all amino acid 
standards were purchased from Sigma Aldrich (St. Louis, MO). D-glucose was purchased 
from Gibco (Life Technologies Corp., Grand Island, NY) and sodium tetraborate 
decahydrate was purchased from CHEM-IMPEX Int’l Inc. (Wood Dale, IL). 
Buffers and Solutions. All solutions were prepared in DI water (Milli-Q, 18.2 
MΩ; Millipore, Bedford, MA) and filtered (0.22 µm). Ringer’s solution was prepared 
with NaCl (123 mM), CaCl2 (1.53 mM), KCl (4.96 mM) and 5 mM glucose with pH 
adjusted to 7.5. aCSF was comprised of NaCl (145 mM), KCl (2.7 mM), MgSO4 (1.0 
mM) and CaCl2 (1.2 mM). The conditioning of microdialysis probes is the only instance 
in which aCSF was used during experimentation. Sheath flow buffer was comprised of 90 
mM borate adjusted to pH 10 and CE separation buffer contained 90 mM borate/35 mM 
α-cyclodextrin (food grade, lot 010760F206, Cyclodextrin Technologies Development 
Inc., Alachua, FL) adjusted to pH 10. Insulin stimulation solution was prepared by 
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dissolving 2U/kg insulin in 0.1 mL Ringer’s solution. Derivatization solution was 
prepared by dissolving 40 mM NBDF (TCI America, Portland, OR) in methanol and 
mixing 1:1 with 500 µM HCl, producing a final concentration of 20 mM NBDF/250 µM 
HCl in 50% methanol. Derivatization solution was prepared daily and degassed under 
vacuum for 2 minutes prior to use. 
 
4.3.2 Microdialysis 
Microdialysis probes were constructed in-house using a side-by-side geometry as 
previously reported101 (see Figure 4.1). Two 40 µm i.d. × 105 µm o.d. fused silica 
capillaries (Polymicro Technologies, Phoenix, AZ) were inserted into a 200 µm diameter 
hollow fiber, regenerated cellulose dialysis membrane (13 kD MWCO, Spectrum 
Laboratories, Rancho Dominquez, CA) and off-set by 3 mm to generate a sampling 
region. Capillaries were sealed in place using polyimide resin (Alltech, Deerfield, IL). 
Prior to use probes were conditioned with ethanol (55 µL/h for 25 minutes) followed by 
aCSF (55 µL/h for 25 minutes). During analysis probes were perfused with Ringer’s 
solution at 25 µL/h. 
 
4.3.3 Online CE-LIF Instrumentation 
Online Derivatization. Dialysate was transferred to a 250 µm i.d. stainless steel 
cross (Valco Instruments Co. Inc., Houston, TX) in a 40 µm i.d. × 360 µm o.d. fused 
silica capillary (see Figure 4.1). Borate buffer and derivatization solution were introduced 
at the reaction cross at 5 µL/h each. The derivatization reaction proceeded through a 90 
61 
 
cm long, 75 µm i.d. × 360 µm o.d. fused silica capillary, of which a 66 cm portion was 
heated to 80⁰C, by running the capillary through flexible tubing containing water from a 
heating bath (NESLAB EX-7 Digital One heating bath circulator, Thermo, Newington, 
NH). Capillary dimensions and all flow rates produced a reaction time of 5 minutes. 
 
Figure 4.1. Schematic of the high-speed online MD-CE-LIF instrument. Probes are implanted into inguinal 
adipose tissue or quadriceps skeletal muscle, and then perfused with Ringer’s solution (A). Perfusate (B) 
mixes with borate buffer and NBDF through a heated reaction capillary prior to injection onto the CE 
separation capillary. A flow gated interface allows for the reaction capillary (C) and separation capillary 
(D) to be coaxially aligned across the separation buffer channel (E-F). 
62 
 
 
High-Speed CE. Discrete sample plugs from the reaction capillary were injected 
onto a 6.2-6.5 cm long, fused silica CE separation capillary (5 µm i.d. × 360 µm o.d.) 
using a flow gated interface.96 The separation and reaction capillaries were coaxially 
aligned leaving an approximately 50 µm gap in-between. Separation buffer was pumped 
through this spacing at 40 mL/h using a syringe pump (Pump 22 syringe pump, Harvard 
Apparatus, Holliston, MA). To perform an injection, buffer flow was stopped for 750 ms 
using a pneumatically actuated valve (C2-3000A 10 port valve, Valco Instruments Co. 
Inc., Houston, TX) controlled by an in-house developed LabView program. Following 
this delay, -19 to -21 kV of injection voltage was applied at the outlet of the separation 
capillary for 100 ms. Buffer crossflow was then resumed as the potential was increased to 
the separation voltage (-21 to -23 kV) over a period of 500 ms. 
Detection Scheme. Laser-induced fluorescence (LIF) detection was performed 
using the 488 nm line of a 60 mW diode pumped solid-state laser (Coherent, Santa Clara, 
CA). The laser beam was expanded using a 10× beam expander (Edmund Optics Inc., 
Barrington, NJ) and focused directly beneath the outlet of the separation capillary, in a 
sheath flow cuvette,123 using a 1× lens. A 60×, 0.7 NA long working distance objective 
(Universe Kogaku, Oyster Bay, NY) collected fluorescence at 90⁰. Collected emission 
was passed through spatial (~1 mm) and bandpass filters (543.5 ± 10 nm) and detected 
using a photomultiplier tube (PMT R1477, Hamamatsu Corp., Bridgewater, NJ). Current 
was filtered with a 10 ms rise time, amplified (Keithley Instruments Inc., Cleveland, OH) 
and recorded using a data acquisition card (National Instruments Corp., Austin, TX). 
Data was analyzed using Cutter Analysis 7.0.124  
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4.3.4 In Vivo Characterization 
All animal experiments were performed in strict compliance to the protocol 
approved by IACUC at the University of Minnesota. Mice were housed in RAR facilities 
and fed a standard chow diet. Prior to all experiments, mice experienced a 4 hour daytime 
fast. Male C57BL6 mice (20-25 g, 6-7 weeks of age; Envigo, Indianapolis, IN) were 
initially anesthetized in an induction chamber (Harvard Apparatus, Holliston, MA) using 
isoflurane (5% in 1 L/min medical grade oxygen; Piramal Critical Care Inc., Bethlehem, 
PA). After sedation mice were fitted with an anesthesia mask (Scivena Scientific, 
Clackamas, OR) for maintenance of surgical anesthesia levels (2.5% isoflurane in 1 
L/min oxygen). Microdialysis probes were implanted into the tissue of interest once the 
mouse was unresponsive to pedal and hind limb reflex testing. After insertion, the needle 
was pulled out of the tissue carefully, leaving the microdialysis probe in place. The probe 
was then secured and allowed to equilibrate for 15-30 minutes before basal 
concentrations were recorded. CE separations were performed every 22 s.  Following 15-
20 minutes of basal recordings, insulin stimulations were administered intravenously 
through the tail vein (0.1 mL of 2U/kg insulin). 
 
4.4 Results and Discussion 
4.4.1 Microdialysis Probe Implantation into Inguinal Adipose Tissue 
 Once the inguinal adipose tissue depot was selected as the sampling location for 
WAT, a protocol was developed to allow for reproducible implantation of the 
microdialysis probe with no damage to the probe membrane and minimal disturbances to 
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surrounding tissues. The initial concept was to use a hollow needle in an approach similar 
to a guide cannula. A microdialysis probe, with its fairly flexible sampling region, might 
deviate from the intended path if inserted directly into the soft tissue on its own. There is 
also risk of damage to the dialysis membrane if the probe tip is forced through the skin 
and various tissues unprotected. Guiding a hollow needle into the tissue of interest first 
would ensure that the desired position was achieved, and subsequent threading of the 
probe through the needle would allow the probe to remain protected. In order to minimize 
tissue disturbances, the smallest needle possible needed to be utilized. 
 Needles ranging from 16G to 22G were tested for their ease in microdialysis 
probe threading. The sampling region of the probe is only 200 µm in diameter, and 
therefore it could theoretically be threaded through all selected gauges. However, the 
probe must be threaded precisely through the needle, it cannot “miss” the needle opening 
and hit the inner walls, as damage to the membrane would be a likely outcome. Since 
threading the probe would be done at the benchtop during an experiment, a microscope 
would be unable to be utilized. Therefore a minimum of 18G allowed for reproducible 
threading. The needle must then be retracted over the probe, once insertion is complete, 
to leave only the probe in place within the tissue. The probe has a “jacket” above the 
membrane to keep the inlet and outlet capillaries securely in place. Needle selections 
must also be able to accommodate this encasement as well. A 19G needle was therefore 
determined the needle insertion choice due to it being the smallest size which would 
easily and comfortably be threaded back over the probe. 
 Implantation into inguinal adipose tissue was initially attempted by inserting the 
needle directly down into the tissue with the mouse positioned on its back. The needle 
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was inserted perpendicularly while the skin around the hind limb joint was stretched taut 
to ease insertion through the skin. Implantation into solely adipose tissue utilizing this 
technique proved exceedingly difficult. The inguinal adipose tissue depot is extremely 
thin and subcutaneous. The needle and microdialysis probe were frequently inserted too 
deep, sampling instead from the underlying skeletal muscle beneath the adipose tissue. 
 A successful and reproducible implantation protocol was developed by inserting 
the needle while maintaining a parallel approach to the abdominal cavity. The mouse was 
positioned on its back and the left hind limb was gently stretched outwards to create taut 
skin above the inguinal adipose tissue depot. The microdialysis probe was threaded 
through the 19G hollow needle until the tip of the probe was flush with the needle outlet. 
Keeping the needle and probe parallel to the abdomen, implantation began slightly 
inferior to the hind limb joint, and proceeded until approximately 0.3-0.7 cm of the 
needle had been inserted. The probe’s inlet and outlet capillaries were then grasped 
securely behind the needle to prevent the probe from shifting, while the needle was 
retracted carefully over the probe. Once complete needle retraction was accomplished, 
the probe was secured in place to prevent movement in the tissue for the remainder of the 
experiment.  
 Figure 4.2 displays an image of the microdialysis probe within the inguinal depot. 
The adipose tissue has been dissected away from the abdominal cavity and the hind limb 
muscle (located dorsally to inguinal adipose tissue). The location of the probe in inguinal 
adipose tissue was visually verified following each in vivo experiment by full dissection. 
Probes were also removed from adipose tissue post dissection to examine the dialysis 
membrane for damage.  
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Figure 4.2. Verification of microdialysis probe placement in the inguinal adipose tissue. After completion 
of the MD-CE experiments, the mouse was euthanized and dissected to expose the inguinal fat depot. The 
microdialysis probe has been outlined. It can be visually verified that the sampling region of the probe is 
located within adipose tissue. 
 
 A reproducible implantation protocol was developed to insert microdialysis 
probes with minimal tissue disturbances and no damage to the probe membrane within 
inguinal adipose tissue. Once probes had equilibrated in the tissue for 15-30 minutes, 
bioamine basal recordings were collected.  
 
4.4.2. Amino Acid Signature of Adipose Tissue 
 CE separations were performed every 22 seconds on dialysate collected from 
inguinal adipose tissue. A total of twelve amines were able to be resolved and detected in 
adipose tissue at concentrations significantly higher than the LOD as shown in Figure 
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5.3A. The separation time was set at 20 seconds, however all detectable amines were 
separated within 15 seconds. Figure 5.3A displays an electropherogram collected under 
basal conditions, with the unlabeled peaks in the electropherogram corresponding to by-
products of the derivatization reaction. Analytes of interest, including isoleucine, leucine, 
valine, glutamine, and alanine, were able to be detected in adipose tissue. Isoleucine and 
leucine were able to be separated and individually identified, despite the sacrifices in 
resolution to improve the temporal response. 
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Figure 4.3. (A) Electropherogram of amino acids at basal levels in inguinal adipose tissue. Peaks identified 
as (1) arginine, (2-3) lysine, (4) isoleucine, (5) leucine, (6) methionine, (7) phenylalanine, (8) valine, (9) 
GABA, (10) glutamine, (11) alanine, (12) glycine, (13) taurine. (B) Electropherograms of basal amino 
acids from adipose tissue of four different mice. 
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 In order to ensure the amino acid profile of adipose tissue was reproducible 
between mice, basal recordings were examined across four different subjects. Figure 5.3B 
displays the amino acid profiles of different mice. As shown, the amino acid signature of 
adipose tissue was found to be remarkably reproducible. An interesting discovery was the 
absence of glutamate in all mice examined. This finding was unexpected, given the 
anticipated concentrations of BCAAs125,126 and due to the known ability of adipose tissue 
to regulate BCAA metabolism,30,31 the presence of downstream metabolism products was 
expected. It is possible for some glutamate to be present in the examined adipose tissue, 
just at concentrations below the LOD. One hypothesis is that within adipose tissue, 
glutamine is preferred to be present and therefore glutamate is converted to glutamine. 
Studies have shown that the activity of the phosphate-dependent glutaminase, which 
requires glutamine, to be greater in adipose tissue than in the liver. It has also been 
discovered that when tricylglycerol formation and lipogenesis are preferred, adipose 
tissue converts glutamine to glutamate, and then metabolizes glutamate to acetyl-CoA 
products for lipogenesis.165 
 
4.4.3 Microdialysis Probe Implantation into Skeletal Muscle 
 Amino acid metabolism in skeletal muscle was a desired point of comparison with 
adipose tissue due to muscle’s known role in protein metabolism. Skeletal muscle’s 
protein synthesis and degradation act as the supply of plasma amino acids during fasting 
states.166 Therefore an implantation protocol for skeletal muscle had to be developed. 
 The inguinal adipose tissue depot chosen for microdialysis probe implantation 
was located near the left hind limb. The left inguinal depot was selected due to ease of 
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orientation with the mouse positioned on its back for the probe in relation to the CE 
instrument. Although currently only one probe is anticipated to be inserted into tissue at a 
time, future experiments may desire bioamine dynamics from both skeletal muscle and 
adipose tissue simultaneously. The insertion procedure developed for skeletal muscle was 
designed to allow for future collections of dialysate from skeletal muscle while sampling 
was occurring in adipose tissue, and vice versa. Skeletal muscle from the right quadriceps 
was chosen as the probe sampling location. 
 Microdialysis probe implantation into skeletal muscle proceeded with the same 
hollow needle approach as outlined for adipose tissue. The probe was threaded through a 
19G hollow needle until the tip of the probe was flush with the needle outlet. The skin 
above the right hind limb quadriceps was pulled taut to ease insertion. Once the needle 
and probe were in the desired sampling location, the outlet and inlet capillaries of the 
probe were firmly grasped while the needle was retraced to prevent any deviation of the 
probe in muscle. After the needle was fully retracted, the microdialysis probe was 
secured in place. Verification of the probe’s placement in quadriceps skeletal muscle can 
be visualized in Figure 4.4. 
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Figure 4.4. Verification of microdialysis probe placement in the right quadriceps skeletal muscle. After 
completion of the MD-CE experiments, the mouse was euthanized and dissected to expose the tissue. The 
microdialysis probe has been outlined. It can be visually verified that the sampling region of the probe is 
located within skeletal muscle. 
 Initially, probe implantation into skeletal muscle utilized the parallel approach 
which was successful for adipose tissue. The needle and probe were kept parallel to the 
abdomen, beginning insertion slightly inferior to the joint area of the right hind limb, and 
proceeding until 0.3-0.7 cm of the needle was inserted into tissue. Instead of keeping the 
needle subcutaneous, insertion began at a more dorsal location on the hind limb, with the 
mouse still positioned on its back. This procedure did not prove to be reproducible 
however, with varying depths into skeletal muscle attained each time. Several insertions 
also resulted in partial insertion into adipose tissue as well. 
 A successful insertion approach into skeletal muscle was achieved by keeping the 
needle and probe at a 45º angle instead of parallel during implantation. Insertion began 
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slightly inferior to the right hind limb joint, and proceeded at a 45º angle towards the 
patella joint. Once the needle had entered the tissue approximately 0.3-0.7 cm, the needle 
was retracted to leave only the microdialysis probe in skeletal muscle. Probes were 
visually verified for their successful insertion into skeletal muscle following each in vivo 
experiment by full dissection, and probes were removed and examined post dissection to 
verify no membrane damage was incurred. Once probes had been allowed to equilibrate 
in skeletal muscle for 15-30 minutes, basal recordings were collected.  
 
4.4.4 Amino Acid Signature of Skeletal Muscle 
 CE separations were performed every 22 seconds in skeletal muscle. Thirteen 
amines were able to be detected and identified in skeletal muscle, as shown in Figure 
4.5A. As in adipose tissue, all amines were separated in under 15 seconds, with unlabeled 
peaks in the electropherograms corresponding to by-products of the derivatization 
reaction. Isoleucine and leucine were still able to be separated and individually identified, 
however their resolutions were significantly decreased. In fact, all resolutions were 
reduced in basal skeletal muscle traces as compared to adipose tissue. No separation 
conditions were altered to potentially cause this change. It would be expected that the 
change in tissue density would affect the tortuosity of amine diffusion for microdialysis 
sampling. This would affect solely relative recovery of the probe between these tissues. It 
can be postulated at this time that the differences in the sampled chemical matrix between 
adipose tissue and skeletal muscle are responsible for the diminished resolution observed, 
as that is the only changing variable in the separations.  
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Figure 4.5. (A) Electropherogram of amino acids at basal levels in skeletal muscle. Peaks identified as (1) 
arginine, (2-3) lysine, (4) isoleucine, (5) leucine, (6) methionine, (7) phenylalanine, (8) valine, (9) GABA, 
(10) glutamine, (11) alanine, (12) glycine, (13) taurine, (14) glutamate. (B) Electropherograms of basal 
amino acids from skeletal muscle of three different mice.  
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Reproducibility of skeletal muscle’s amino acid signature was verified in Figure 
4.5B. As shown, the presence of the same amino acids is reproducible in three mice. 
Decreased resolution can be visualized in all electropherograms, supporting the 
hypothesis that a change found in the chemical matrix of skeletal muscle as compared to 
adipose tissue is responsible. Another interesting discovery was the presence of glutamate 
in all skeletal muscle basal recordings. Although present in significantly less quantities 
than isoleucine, leucine, valine, glutamine, and alanine, it is easily identifiable above 
baseline.  
 
4.4.5 MD-CE Analysis of Bioamine Dynamics in Adipose Tissue 
 In order to fully understand the roles BCAAs play in overall body metabolism, 
their dynamics must be characterized as they respond to various metabolic stimuli. The 
online MD-CE assay is able to perform an analysis every 22 seconds, allowing dynamic 
changes to be recorded in near real time. As a demonstration, an intravenous injection of 
2 U/kg insulin into the tail vein was given to a mouse. The microdialysis probe was 
implanted in inguinal adipose tissue, to record fat tissue’s response to this systemic 
stimuli. The MD-CE assay was able to record basal measurements before the injection, 
during the initial stimulus, and through the refractory period as analyte concentrations re-
stabilized. Basal levels recorded before stimulation allow relative changes to be assessed, 
with each mouse acting as its own control. Relative changes in analyte concentrations are 
commonly reported in microdialysis assays as compared to absolute concentrations since 
they do not depend on the validity of in vitro calibration, which may or may not 
accurately predict in vivo recovery. 
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Figure 4.6 displays the resulting dynamics induced via a systemic insulin 
stimulation. As shown in Figure 5.6A-C, basal levels of each amino acid were recorded 
for approximately eight minutes following a 20 minute probe equilibration period. The 
vertical line on each graph denotes the time at which the insulin stimulation was injected. 
Valine, alanine, and taurine levels increased markedly in adipose tissue within 5 minutes 
of the insulin injection before returning to an elevated baseline. Valine’s peak height 
Figure 4.6. Valine (A), alanine (B) and taurine (C) traces in adipose tissue as insulin 
stimulation is applied. The time of stimulation is denoted on each graph by the drawn arrow. 
Amino acids responded with an increase within 5 minutes, before returning to an elevated 
baseline. Controls for each amino acid are displayed in (D). 
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increased 40% during the initial response before returning to a baseline elevated by 34% 
over original basal levels. Alanine’s peak height initially increased by 46% with average 
levels post stimulation remaining elevated by 16%. Taurine’s peak height increased by 
37% during the initial stimulus before returning to an elevated baseline, 21% higher than 
the original basal levels. Average post stimulation levels for all three amino acids were 
significantly different than the original basal levels (p < 0.001). Figure 5.6D displays the 
negative control for each amino acid, in which their levels were monitored in inguinal 
adipose tissue without any stimulus. As shown, the levels of each amino acid do not 
drastically spike in the control data. Due to the negative control and individual bioamine 
results which showed initial spikes to varying degrees, it can be determined with 
confidence that the observed changes in Figures 5.6A-C are the result of induced 
biological dynamics from the insulin stimulation and not instrumental fluctuations.  
 In the same manner with which valine, alanine, and taurine were monitored every 
22 seconds throughout a stimulation event, all other bioamines separated and identified in 
adipose tissue could be monitored as well. These three amino acids displayed the most 
significant changes due an insulin stimulation, and they all are of interest due to the 
metabolism-related goal of this research. Valine, as a BCAA, acts as a nutrient signal to 
the peripheral nervous system, regulates energy balance and appetite, and promotes 
protein synthesis and degradation.19,22 Alanine is derived from BCAA metabolism and 
the degradation of pyruvate, and is linked to metabolic pathways such as the citric acid 
cycle, gluconeogenesis, and glycolysis. Taurine has also been shown to improve 
metabolism in animal studies, suggesting that supplementation could aide in the treatment 
of type 2 diabetes.167  
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4.5 Conclusion 
 This work integrated an online MD-CE assay capable of 22 second temporal 
resolution with in vivo sampling from inguinal adipose tissue and quadriceps skeletal 
muscle. An implantation procedure was developed for both tissues, utilizing a 19G 
hollow needle to minimize disturbances to surrounding tissue and providing precise 
probe placement. Following each experiment, probe placement and an intact probe 
membrane were visually verified by a full dissection. The presence of 12 and 13 
bioamines were identified in adipose tissue and skeletal muscle, respectively. Both 
tissues demonstrated reproducible amino acid signatures between mice. To demonstrate 
the ability of the developed implantation procedure and online MD-CE assay for 
monitoring induced biological dynamics, an insulin stimulation was administered. Valine, 
alanine, and taurine levels were found to spike within 5 minutes, and post-stimulation 
levels remained significantly elevated compared to original basal levels in adipose tissue. 
This proved the ability of this assay to monitor in vivo dynamics on a 22 second 
timescale. Future studies will focus on applying a variety of stimulations to aide in 
determining the full role of BCAAs in adipose tissue’s metabolism and energy regulation.  
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Chapter 5 
In Vivo Monitoring of Induced Metabolism Dynamics in 
Adipose Tissue and Skeletal Muscle 
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5.1 Summary 
 Bioamines were monitored in adipose tissue and skeletal muscle while 
biologically relevant stimuli were administered to mice under anesthesia. Amino acid 
levels were recorded prior to, during, and post stimulation. All stimulations were 
administered through retrodialysis, directly into the tissue of interest, for a total of five 
minutes. 
 A 20 mM glucose stimulation was administered to four mice, with bioamine 
levels recorded in inguinal adipose tissue, and to three mice with results recorded in 
quadriceps skeletal muscle. In both tissues, no reproducible dynamics were observed for 
alanine, leucine, valine, or taurine. It was initially hypothesized that glucose wasn’t 
evoking a strong response in the tissue due to its ability to be easily metabolized through 
glycolysis. Therefore the next stimuli chosen were artificial sweeteners, to compare their 
elicited response to that of glucose. 
 Saccharin (10 mg/kg) and ace K (2.4 mg/kg) were administered to three and two 
mice, respectively, with bioamines monitored in adipose tissue. For both stimulations, no 
reproducible trend emerged for alanine, leucine, valine, or taurine. The random responses 
observed from different mice appears to indicate that while the stimulation was 
administered directly to the tissue, it most likely is being immediately dispersed 
throughout the body, carried by plasma. This would cause the stimulus to be quickly 
diluted below the effective concentration administered. All body systems would also then 
be affected by this stimulus, and therefore responses recorded in adipose tissue do not 
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exhibit a dramatic and reproducible change, due to other tissues metabolizing the 
stimulus instead. 
 
5.2 Introduction 
 Plasma BCAA levels have been found to be elevated in obese individuals as well 
as those with type 2 diabetes.21,28,29 BCAA levels have also been found to be one of the 
best indicators of metabolic dysregulation, often appearing in advance of increased 
fasting glucose levels.21,28 Adipose tissue is known to regulate BCAA levels,30,31 as well 
as participate in the metabolism signaling network with the brain, liver, muscle, and 
pancreas.10-12 In order to fully establish these bioamines as biomarkers for metabolic 
dysregulation, their dynamics under various metabolic conditions must be fully 
understood. Current research is limited in its time response for monitoring these 
bioamines, with typical analysis times ranging from minutes to hours.119-121 Metabolism 
dynamics occur on a much faster timescale, and thus they must be monitored in as close 
to near real time as possible.  
 The body metabolizes glucose through glycolysis, to produce pyruvate, ATP, and 
NADH. ATP provides the necessary energy for the body to perform a variety of 
functions, and NADH is a coenzyme involved in the release of energy.168 Induced 
bioamine metabolism dynamics will therefore be monitored as a response to glucose in 
near real time. In this way, it will be possible to examine these bioamines as adipose 
tissue is actively involved in metabolism. Glucose stimulations will also be administered 
to skeletal muscle to observe dynamics occurring in this tissue. Skeletal muscle, with its 
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protein synthesis and degradation supplying plasma amino acids during fasting states,166 
is an interesting point of comparison for adipose tissue’s metabolism. 
 Initial FDA studies have found artificial sweeteners to be safe for human 
consumption, however recent findings have demonstrated saccharin and ace K to promote 
new adipocyte growth.169 Preliminary studies conducted in vitro have displayed 
differences in amino acid metabolism in adipocytes – varying degrees of BCAA uptake 
and presence of downstream metabolites – when incubated with artificial sweeteners as 
compared to glucose.170 With a high prevalence of artificial sweeteners in food and 
beverages consumed, the metabolic dynamics induced by artificial sweeteners should be 
examined as well. By comparing these dynamics with those induced by glucose, it can be 
determined whether or not the consumption of artificial sweeteners yields differing 
metabolic dynamics in adipose tissue on the timescale of seconds. This could explain 
why the increased use of artificial sweeteners throughout the years also corresponds to an 
increase in obesity within the United States.2 
 
5.3 Materials and Methods 
5.3.1 Chemicals and Reagents 
Chemicals. Insulin (human recombinant, lot 15L255-B), saccharin, ace K, and all 
amino acid standards were purchased from Sigma Aldrich (St. Louis, MO). D-glucose 
was purchased from Gibco (Life Technologies Corp., Grand Island, NY) and sodium 
tetraborate decahydrate was purchased from CHEM-IMPEX Int’l Inc. (Wood Dale, IL).  
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Buffers and Solutions. All solutions were prepared in DI water (Milli-Q, 18.2 
MΩ; Millipore, Bedford, MA) and filtered (0.22 µm). Ringer’s solution was prepared 
with NaCl (123 mM), CaCl2 (1.53 mM), KCl (4.96 mM) and 5 mM glucose with pH 
adjusted to 7.5. aCSF was comprised of NaCl (145 mM), KCl (2.7 mM), MgSO4 (1.0 
mM) and CaCl2 (1.2 mM). The conditioning of microdialysis probes is the only instance 
in which aCSF was used during experimentation. Sheath flow buffer was comprised of 90 
mM borate adjusted to pH 10 and CE separation buffer contained 90 mM borate/35 mM 
α-cyclodextrin (food grade, lot 010760F206, Cyclodextrin Technologies Development 
Inc., Alachua, FL) adjusted to pH 10. Insulin stimulation solution was prepared by 
dissolving 2U/kg insulin in 0.1 mL Ringer’s solution. 20 mM glucose and 0.853 M ace K 
solutions were prepared in Ringer’s solution. Saccharin stimulation solution was prepared 
by dissolving 10 mg of saccharin per kg of mouse in 1.0 mL Ringer’s solution 
(approximately 1.36 mM saccharin solution). Derivatization solution was prepared by 
dissolving 40 mM NBDF (TCI America, Portland, OR) in methanol and mixing 1:1 with 
500 µM HCl, producing a final concentration of 20 mM NBDF/250 µM HCl in 50% 
methanol. Derivatization solution was prepared daily and degassed under vacuum for 2 
minutes prior to use. 
 
5.3.2 Microdialysis 
Microdialysis probes were constructed in-house using a side-by-side geometry as 
previously reported101 (see Figure 4.1). Two 40 µm i.d. × 105 µm o.d. fused silica 
capillaries (Polymicro Technologies, Phoenix, AZ) were inserted into a 200 µm diameter 
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hollow fiber, regenerated cellulose dialysis membrane (13 kD MWCO, Spectrum 
Laboratories, Rancho Dominquez, CA) and off-set by 3 mm to generate a sampling 
region. Capillaries were sealed in place using polyimide resin (Alltech, Deerfield, IL). 
Prior to use probes were conditioned with ethanol (55 µL/h for 25 minutes) followed by 
aCSF (55 µL/h for 25 minutes). During analysis probes were perfused with Ringer’s 
solution at 25 µL/h. 
 
5.3.3 Online CE-LIF Instrumentation 
Online Derivatization. Dialysate was transferred to a 250 µm i.d. stainless steel 
cross (Valco Instruments Co. Inc., Houston, TX) in a 40 µm i.d. × 360 µm o.d. fused 
silica capillary (see Figure 4.1). Borate buffer and derivatization solution were introduced 
at the reaction cross at 5 µL/h each. The derivatization reaction proceeded through a 90 
cm long, 75 µm i.d. × 360 µm o.d. fused silica capillary, of which a 66 cm portion was 
heated to 80⁰C, by running the capillary through flexible tubing containing water from a 
heating bath (NESLAB EX-7 Digital One heating bath circulator, Thermo, Newington, 
NH). Capillary dimensions and all flow rates produced a reaction time of 5 minutes. 
High-Speed CE. Discrete sample plugs from the reaction capillary were injected 
onto a 6.2-6.5 cm long, fused silica CE separation capillary (5 µm i.d. × 360 µm o.d.) 
using a flow gated interface.96 The separation and reaction capillaries were coaxially 
aligned leaving an approximately 50 µm gap in-between. Separation buffer was pumped 
through this spacing at 40 mL/h using a syringe pump (Pump 22 syringe pump, Harvard 
Apparatus, Holliston, MA). To perform an injection, buffer flow was stopped for 750 ms 
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using a pneumatically actuated valve (C2-3000A 10 port valve, Valco Instruments Co. 
Inc., Houston, TX) controlled by an in-house developed LabView program. Following 
this delay, -19 to -21 kV of injection voltage was applied at the outlet of the separation 
capillary for 100 ms. Buffer crossflow was then resumed as the potential was increased to 
the separation voltage (-21 to -23 kV) over a period of 500 ms. 
Detection Scheme. Laser-induced fluorescence (LIF) detection was performed 
using the 488 nm line of a 60 mW diode pumped solid-state laser (Coherent, Santa Clara, 
CA). The laser beam was expanded using a 10× beam expander (Edmund Optics Inc., 
Barrington, NJ) and focused directly beneath the outlet of the separation capillary, in a 
sheath flow cuvette,123 using a 1× lens. A 60×, 0.7 NA long working distance objective 
(Universe Kogaku, Oyster Bay, NY) collected fluorescence at 90⁰. Collected emission 
was passed through spatial (~1 mm) and bandpass filters (543.5 ± 10 nm) and detected 
using a photomultiplier tube (PMT R1477, Hamamatsu Corp., Bridgewater, NJ). Current 
was filtered with a 10 ms rise time, amplified (Keithley Instruments Inc., Cleveland, OH) 
and recorded using a data acquisition card (National Instruments Corp., Austin, TX). 
Data was analyzed using Cutter Analysis 7.0.124  
 
5.3.4 In Vivo Characterization 
All animal experiments were performed in strict compliance to the protocol 
approved by IACUC at the University of Minnesota. Mice were housed in RAR facilities 
and fed a standard chow diet. Prior to all experiments, mice experienced a 4 hour daytime 
fast. Male C57BL6 mice (20-25 g, 6-7 weeks of age; Envigo, Indianapolis, IN) were 
85 
 
initially anesthetized in an induction chamber (Harvard Apparatus, Holliston, MA) using 
isoflurane (5% in 1 L/min medical grade oxygen; Piramal Critical Care Inc., Bethlehem, 
PA). After sedation mice were fitted with an anesthesia mask (Scivena Scientific, 
Clackamas, OR) for maintenance of surgical anesthesia levels (2.5% isoflurane in 1 
L/min oxygen). Microdialysis probes were implanted into the tissue of interest once the 
mouse was unresponsive to pedal and hind limb reflex testing. After insertion, the needle 
was pulled out of the tissue carefully, leaving the microdialysis probe in place. The probe 
was then secured and allowed to equilibrate for 15-30 minutes before basal 
concentrations were recorded. CE separations were performed every 22 seconds.  
Following basal recordings, stimulations were administered through retrodialysis for a 
period of five minutes. 
 
5.4 Results and Discussion 
5.4.1. Glucose Stimulation in Adipose Tissue 
 Initial stimulus experiments sought to expand on previous in vitro work done by 
Dr. Rachel Harstad, a former Bowser group researcher.46 Dr. Harstad cultured 3T3-L1 
adipocytes, which were then exposed to glucose and excess BCAAs. In vitro analysis 
concluded that in the presence of glucose, BCAAs were uptaken by adipocytes. Various 
concentrations of glucose were examined for their effect on adipocyte uptake. Glucose 
was selected as the first stimulation to be administered to adipose tissue with the intention 
of comparing the in vitro and in vivo assays. 
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 Microdialysis probes were successfully implanted into inguinal adipose tissue of 
four different mice. A 20 mM glucose stimulation was provided via retrodialysis for five 
minutes, with bioamine levels monitored prior to, during, and post stimulation. Figure 5.1 
displays the resulting traces for alanine, leucine, valine, and taurine (A → D 
respectively). Each bioamine’s level was recorded every 22 seconds. The traces are 
expressed as time post stimulation, with the time of administered stimulus being denoted 
as 0 minutes, and levels recorded for 50 to 90 minutes post stimulation. The bar on each 
graph denotes the time at which an induced change would be expected to reach the 
detector. Dynamic changes were assessed as the percentage of peak height change 
compared to average basal levels. By assessing dynamics as relative changes, as opposed 
to absolute concentrations, each animal is able to act as its own control. 
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Figure 5.1. (A) Alanine, (B) leucine, (C) valine, and (D) taurine traces in adipose tissue of four mice 
during a 20 mM glucose stimulation. Bioamines were monitored prior to, during, and post stimulation. 
Administration of the stimulus occurred at time 0 on the recorded traces, and proceeded for 5 minutes. The 
bar indicates when induced dynamics are expected to reach the detector. 
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Figure 5.1. (A) Alanine, (B) leucine, (C) valine, and (D) taurine traces in adipose tissue of four mice 
during a 20 mM glucose stimulation. Bioamines were monitored prior to, during, and post stimulation. 
Administration of the stimulus occurred at time 0 on the recorded traces, and proceeded for 5 minutes. The 
bar indicates when induced dynamics are expected to reach detector. 
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 As shown in Figures 5.1A-D, no reproducible dynamic changes were observed in 
adipose tissue for alanine, leucine, valine, or taurine due to a 20 mM glucose stimulation. 
Each trace initially fluctuates around 100% change in percentage peak height (100% 
being equivalent to the average basal peak height, with any deviation representing a 
change from basal levels). The traces have been manually offset from one another for 
ease of visualization. Some dramatic changes are observed, such as the decrease in peak 
height from trial 1 around 70 minutes post stimulation, however that exact change was 
observed in all bioamine traces. This is therefore hypothesized to be the result of 
instrumental fluctuations and not due to metabolism dynamics. The same principle holds 
true for the sharp declines in trial 2 at 37 and 45 minutes. Regardless, no bioamine traces 
demonstrated reproducible fluctuations with other trials, and therefore glucose was 
determined to induce no reproducible metabolism dynamics in adipose tissue at 20 mM 
delivered through retrodialysis.  
 It was hypothesized that no dynamics were established for glucose stimulations 
due to the body’s ability to readily regulate circulating glucose. The next stimulation 
utilized an artificial sweetener, as a means to test whether the mouse’s metabolism 
reacted differently to saccharin and ace K as compared to glucose. 
 
5.4.2. Saccharin Stimulation in Adipose Tissue 
 Saccharin was administered via retrodialysis to inguinal adipose tissue for five 
minutes. The saccharin stimulation was set at 10 mg/kg (10 mg of saccharin per 1 kg of 
mouse), or twice the ADI, and was dissolved in 1 mL of Ringers’ solution. The mice 
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utilized in the previous glucose study weighed an average of 25 g, and thus the saccharin 
stimulation solution was prepared for this dosage. Therefore the approximate 
concentration of stimulus was 1.36 mM saccharin. Figure 5.2 displays the traces of 
alanine, leucine, valine, and taurine (A→D respectively) with levels monitored prior to, 
during, and post stimulation. The time of stimulus administration is denoted by 0 minutes 
on the traces, with the bar on each graph representing the time of an expected induced 
dynamic change reaching the detector. 
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Figure 5.2. (A) Alanine, (B) leucine, (C) valine, and (D) taurine traces in adipose tissue of three mice 
during a 10 mg/kg saccharin stimulation. Bioamines were monitored prior to, during, and post stimulation. 
Administration of the stimulus occurred at time 0 on the recorded traces, and proceeded for 5 minutes. The 
bar indicates when the induced dynamics are expected to reach the detector. 
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Figure 5.2. (A) Alanine, (B) leucine, (C) valine, and (D) taurine traces in adipose tissue of three mice 
during a 10 mg/kg saccharin stimulation. Bioamines were monitored prior to, during, and post stimulation. 
Administration of the stimulus occurred at time 0 on the recorded traces, and proceeded for 5 minutes. The 
bar indicates when the induced dynamics are expected to reach the detector. 
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 In Figure 5.2A-D, the traces have not been manually offset. In the case of 
saccharin stimulations, each trial yielded such varying results, that a manual offset was 
not required to view the full trace. A total of three mice were examined for saccharin 
studies, and similar to glucose, no reproducible dynamics were observed for all 
bioamines. 
 Although the saccharin stimulation solution was prepared at twice the ADI (10 
mg/kg), the tissue did not experience the full potency of this solution. As prepared, the 
entire 1 mL represented twice the ADI, but with the stimulation only administered for 
five minutes, that entire volume was not delivered to the tissue. Also, the recovery of the 
microdialysis probe (as determined in Chapter 2.4.4.), was determined to be 
approximately 17% for all analytes of interest. Relative recovery represents the fraction 
of analyte recovered from the tissue, but also signifies the fraction of perfusate, or 
stimulation, that is delivered to the tissue. Based on the amount of volume delivered 
through the probe in five minutes, and accounting for 17% relative recovery, it is 
estimated that the tissue only experienced 0.0035 mg/kg of the intended 10 mg/kg 
saccharin dose. For the next serious of stimulations, the maximum dosage of ace K was 
ensured to be delivered to the tissue, to determine whether a higher concentration of 
stimulus was required to elicit metabolism dynamics in vivo. 
 
5.4.3. Ace K Stimulation in Adipose Tissue 
 The maximum allowed dosage for ace K as per our IACUC protocol is 30 mg/kg, 
or twice the ADI. In order to ensure that this maximum concentration is delivered to the 
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tissue of interest, factors such as total volume delivered and the recovery of the probe 
must be taken into account. 
 The perfusion flow rate through the probe is set at 25 µL/hr. This flow rate is 
optimized for the NBDF derivatization reaction, and thus is consistent throughout all 
experiments. Stimulations are administered for five minutes, which indicates that a total 
volume of 2.083 µL of stimulation solution is delivered through the probe in this time. 
The relative recovery of the microdialysis probe is 17%, which also approximates the 
fraction of stimulant, or ace K, which will be administered to the tissue from the 
stimulation solution. 
 Assuming a 25 g mouse, as was the average for all adipose tissue glucose 
experiments, 30 mg/kg of ace K stimulation would require a total of 0.75 mg, or 3.73 ×
 10−6 moles of ace K to be delivered to adipose tissue within five minutes. To deliver 
3.73 ×  10−6 moles of ace K, in 2.083 µL of stimulation solution, while accounting 17% 
recovery/delivery, the stimulation solution perfused through the probe must be 10.52 M 
ace K. 
 A sugar solution of 10.52 M is not able to be perfused through the microdialysis 
probe, as its viscosity could negatively impact the flow of solution through the 
derivatization capillary. Thus a solution of 0.853 M was prepared instead, which 
corresponds to approximately 2.4 mg/kg ace K. Figure 5.3 displays the traces of alanine, 
leucine, valine, and taurine prior to, during, and post stimulation. The stimulation start 
time is denoted by 0 minutes on the traces below, and the bar represents the time at which 
any induced dynamics reach the detector. 
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Figure 5.3. (A) Alanine, (B) leucine, (C) valine, and (D) taurine traces in adipose tissue of two mice during 
a 2.4 mg/kg ace K stimulation. Bioamines were monitored prior to, during, and post stimulation. 
Administration of the stimulus occurred at time 0 on the recorded traces, and proceeded for 5 minutes. The 
bar indicates when induced dynamics are expected to reach the detector. 
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Figure 5.3. (A) Alanine, (B) leucine, (C) valine, and (D) taurine traces in adipose tissue of two mice during 
a 2.4 mg/kg ace K stimulation. Bioamines were monitored prior to, during, and post stimulation. 
Administration of the stimulus occurred at time 0 on the recorded traces, and proceeded for 5 minutes. The 
bar indicates when induced dynamics are expected to reach the detector. 
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 Traces in Figure 5.3 have been manually offset for ease of visualization. Leucine 
in trial 1 decreased below the LOD following the stimulus, and therefore the system was 
unable to monitor any induced dynamics. It appears that the examined bioamines 
demonstrate a slight increase in peak height around 10 minutes, which is the first time at 
which an induced dynamic would be expected to reach the detector. However, following 
the slight initial increase, trial 1 bioamines decrease throughout the remainder of the 
experiment. Taurine exhibits a similar trace for trial 2, however alanine, leucine, and 
valine in trial 2 remain fairly consistent. The general decrease in trial 1 bioamines could 
be due to a decline in the animal due to anesthesia, however more trials are necessary to 
conclude whether or not this is an induced dynamic. These results appear to show an 
induced dynamic immediately following stimulus administration. This preliminary 
evidence supports the idea that a more concentrated dose of stimulus is required to elicit a 
biological response when administered via retrodialysis. Further studies are required to 
conclude if the responses observed in these trials are induced by ace K. 
 
5.4.4. Glucose Stimulation in Skeletal Muscle 
 With glucose, saccharin, and ace K all yielding no reproducible response in 
induced metabolism dynamics in adipose tissue, it was decided to administer glucose 
stimulation in skeletal muscle. Skeletal muscle is actively involved in protein synthesis 
and degradation, and thus its induced metabolism dynamics are an interesting point of 
comparison against adipose tissue. A 20 mM glucose stimulation was administered to 
quadriceps skeletal muscle for five minutes via retrodialysis. This concentration of 
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glucose was selected due to its previous utilization in adipose tissue studies providing a 
direct line of comparison between the two tissues.  
 
 
Figure 5.4. (A) Alanine, (B) leucine, (C) valine, and (D) taurine traces in skeletal muscle of three mice 
during a 20 mM glucose stimulation. Bioamines were monitored prior to, during, and post stimulation. 
Administration of the stimulus occurred at time 0 on the recorded traces, and proceeded for 5 minutes. The 
bar indicates when induced dynamics are expected to reach the detector. 
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Figure 5.4. (A) Alanine, (B) leucine, (C) valine, and (D) taurine traces in skeletal muscle of three mice 
during a 20 mM glucose stimulation. Bioamines were monitored prior to, during, and post stimulation. 
Administration of the stimulus occurred at time 0 on the recorded traces, and proceeded for 5 minutes. The 
bar indicates when induced dynamics are expected to reach the detector. 
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 The time of stimulus administration is denoted by 0 minutes on each trace, with 
the bar representing when an induced dynamic would reach the detector. Alanine, valine, 
and taurine (Figure 5.4A, C, and D respectively) have not been manually offset. The 
bioamine levels from each trial yielded varying traces that are easily visualized. Leucine, 
displayed in Figure 5.4B, has been manually offset to allow for easier visualization of 
each trace. All traces initially fluctuate around 100% peak height change, which is 
representative of the average basal level. Taurine was only able to be examined in two 
trials, as during the first trial, its signal maxed out the detector for the entire experiment. 
Any efforts to reduce amplification of signal to better examine taurine, resulted in all 
other bioamines not generating enough signal to be monitored. Therefore, no changes 
were able to be assessed in taurine’s signal from trial 1.  
 No reproducible dynamics were observed in skeletal muscle for alanine, leucine, 
valine, or taurine due to a glucose stimulation. It is hypothesized that due to all 
stimulations being administered via retrodialysis, they are in fact not entering and 
affecting the tissue of interest. Instead the stimuli are being quickly diluted and 
distributed through the body to affect all tissues. A higher concentration of stimulus is 
likely required to elicit a biological response from tissues in vivo when administered 
through retrodialysis.  
 Examining bioamine traces, throughout all administered stimuli, induced 
dynamics appear to be potentially present. Several trials in each administered stimuli 
exhibit sharp changes in bioamine peak height around 10 minutes, which is when the 
initial stimulus is expected to reach the detector. With only several trials in each stimulus, 
it is not possible to confidently conclude whether or not the dynamics occurring are due 
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to the stimulus provided.  More trials in each study could produce a pattern of bioamine 
responses that due to animal to animal variability, are not immediately evident after 
several preliminary trials.  
 
5.5 Conclusion 
 Biologically relevant stimulations of glucose, saccharin, and ace K were 
administered through retrodialysis to inguinal adipose tissue and quadriceps skeletal 
muscle. Bioamine traces of alanine, leucine, valine, and taurine were monitored prior to, 
during, and post stimulation, with dynamic changes assessed as the percentage of peak 
height change as compared to the average basal levels. No reproducible dynamics were 
observed as a result of any stimulation administered, even when the stimulation was 
ensured to deliver the maximum dosage directly to the tissue. This is believed to be due 
to the stimulation being diffused throughout the entire body upon delivery, and thus not 
solely affecting the tissue as anticipated. It is also plausible that more trials in each study 
would produce a pattern of induced dynamics. 
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Chapter 6 
Summary and Future Outlook 
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6.1 Summary 
 The described work outlines the development and application of an analytical 
platform capable of monitoring amino acid metabolism dynamics in vivo in near real 
time. The online high-speed CE instrument coupled with microdialysis sampling was 
optimized for near real time analysis of BCAAs and their related metabolites in chapter 2. 
Addition of 35 mM α-cyclodextrin to the separation buffer (90 mM borate, pH=10) 
allowed for the separation of all BCAAs and their downstream metabolites (glutamine, 
alanine, and glutamate).122 All amino acids of interest were able to be identified in a 
standard separation, with modest sacrifices made in resolution to achieve the fastest time 
response possible. LODs ranged from 690 nM to 6.5 µM depending on the analyte 
examined. These calculated LODs were significantly lower than the anticipated 
biological concentrations in adipose tissue and skeletal muscle, and therefore deemed 
sufficient to proceed towards in vivo studies. Microdialysis probe recovery was calculated 
to be between 14% and 18% for all analytes of interest. The temporal response of the 
system was determined to be 22 seconds, a vast improvement over previous utilization of 
this separation assay.122 
 In chapter 3, an entire in vivo protocol was designed and developed to allow for a 
variety of future in vivo experiments. C57BL6 male mice were selected as the model due 
to their frequent use in obesity research.127,128 Male mice were chosen exclusively in 
order to avoid the complexities of mammary glands within adipose tissue depots as found 
in female mice.130,131 The inguinal adipose tissue depot and quadriceps of the hind limb 
were selected as the tissue locations due to their metabolic properties133 and ease of 
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accessibility for microdialysis probe insertion.135 Microdialysis probes were to be 
inserted into tissue locations using a hollow needle, which would be subsequently pulled 
back over the probe to leave only the dialysis membrane in the tissue for sampling. Probe 
insertion was to begin once the mouse was under surgical levels of anesthesia. 
 Isoflurane inhalant anesthetic was chosen for its rapid induction136 and 
recommended use on C57BL6 strains.140 Initial induction was designed to take place in 
an induction chamber, with surgical levels of anesthesia maintained throughout the 
experiment at a nose cone. Euthanasia was set to conclude each experiment by means of 
an intracardiac dose of KCl under anesthesia, followed by a thoracotomy as a secondary 
procedure. A complete and detailed SOP is provided at the conclusion of chapter 3, in the 
attempt to pass along developed animal handling knowledge to potential future 
researchers joining the project.  
 Initial biological experiments were outlined in chapter 4, both in inguinal adipose 
tissue and quadriceps hind-limb muscle. Reproducible microdialysis probe insertion into 
both types of tissue was developed and verified by full tissue dissection following each 
experiment. Probes were also examined post-dissection to ensure the dialysis membrane 
was not damaged during implantation. All amino acids of interest were separated and 
identified within a 15 second separation window. In adipose tissue, 12 amines were 
detected at concentrations significantly higher than the LOD while 13 amines were 
detected in skeletal muscle. Glutamate was not found in adipose tissue in any detectable 
quantity, however its presence was able to be monitored in skeletal muscle. The amino 
acid signature of both tissues was found to be reproducible between different mice.  
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 An insulin stimulation was provided via the tail vein to induce metabolism 
dynamics in adipose tissue. Dynamic changes were able to be observed in several 
bioamines, indicating the developed analytical platform was in fact able to monitor 
induced biological dynamics. Chapter 5 focused on various stimulations provided to 
adipose tissue and skeletal muscle. A glucose stimulation did not yield reproducible 
induced dynamics when provided to either adipose tissue or skeletal muscle. Saccharin 
and ace K stimulations were administered to adipose tissue, both yielding no reproducible 
induced metabolism dynamics. Glucose, saccharin, and ace K stimulations were 
administered to adipose tissue through retrodialysis, and therefore it is possible that the 
stimulations were cleared from the adipose tissue and circulated through the body before 
any noticeable effect on adipose tissue was able to take place. Sampling from various 
other tissue locations (i.e. skeletal muscle), while administering the stimulation still in 
adipose tissue, would allow for determination as to whether other tissues were being 
affected by the stimulation. If metabolism was induced in skeletal muscle from a 
stimulation provided through retrodialysis in adipose tissue, it would indicate the 
stimulation is being cleared from adipose tissue, and circulated throughout the body.  
 
6.2 Future Outlook 
 An analytical platform capable of near real time analysis of metabolism dynamics 
in adipose tissue and skeletal muscle has been fully developed. The separation assay’s 
performance has been characterized and optimized to allow for a 22 second temporal 
resolution, and the reproducible implantation of microdialysis probes into adipose tissue 
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and skeletal muscle was designed and verified. Initial biological stimulations focused on 
induced metabolism dynamics in the inguinal adipose tissue of C57BL6 male mice by 
glucose and artificial sweeteners. Adipose tissue was the predominant tissue of interest 
due to its active role in the signaling network to maintain energy balance13,14 and its 
regulation of circulating BCAA levels.30,31 BCAAs are known to be actively involved in 
insulin secretion,10 protein synthesis and degradation,12 and appetite control,11 as well as 
acting as one of the best predictors of metabolic disorders such as diabetes.21,28 
 Previous in vitro work utilizing adipocytes in an offline analysis demonstrated 
altered metabolism when adipocytes were incubated with glucose and fructose, ace K, 
stevioside, or saccharin. Dr. Rachel Harstad, a former graduate student in Dr. Bowser’s 
lab, discovered that adipocyte incubation with 5 mM glucose and 30 mM fructose 
diminished BCAA uptake as compared to incubation with 5 mM glucose. Incubation with 
5 mM glucose and 64.5 µM stevioside did not further induce BCAA uptake as compared 
to controls, however glutamate release was promoted.170 With these preliminary in vitro 
results, further analysis of metabolism dynamics was desired in vivo, where the result of 
interworking bodily systems could be examined. Glucose, saccharin, and ace K were 
administered as stimuli, however results indicated that no noticeable metabolism 
dynamics were induced. This most likely indicated that at the concentrations provided, 
circulating blood was able to clear the stimulus and diffuse it through the entire body. 
The research thus far indicates that in an in vivo system, at the tested concentrations, 
metabolism did not respond any differently to artificial sweeteners as compared to 
glucose. 
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 The next step in this project would be to examine a variety of concentrations for 
each stimuli, in order to gain pharmacokinetic information. In this way, it could be 
determined if there is a specific concentration of artificial sweeteners and/or glucose in 
which the body begins to experience altered metabolism. The near real time aspect to 
data collection will not only demonstrate at what concentration the stimuli begins 
inducing different metabolism dynamics, but also how the metabolism dynamics are 
altered. Information as to how metabolism dynamics are altered under varying conditions 
of artificial sweetener stimuli would provide key insights into their nutritional use for 
preventing and combating obesity. 
 Another direction for the future of this project would be to reproduce all 
preliminary stimuli and corresponding pharmacokinetic experiments in the inguinal 
adipose tissue depot of ob/ob mice. The ob/ob mouse has a genetic knockout that 
prevents the hormone leptin from being produced.171 Leptin plays a significant role in 
appetite signaling to the brain,172 and thus without it, mice consume food excessively. 
Mice then gain an extreme amount of weight and frequently develop high blood sugar. 
This mouse phenotype is frequently used in metabolism, obesity, and type 2 diabetes 
studies. Reproducing these stimuli experiments in this model would provide insight into 
potential altered metabolism dynamics in adipose tissue when in an obese or type 2 
diabetic state.  
A final alternative direction for the future of this project would involve switching 
focus from adipose tissue to skeletal muscle as the predominant tissue of interest. Skeletal 
muscle constitutes approximately 40-50% of total body mass in the average adult male,173 
and with its significant role in glucose regulation174 and protein storage,175 changes in its 
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metabolism would have an immense impact on the body’s overall metabolism and energy 
regulation.176 While muscle metabolism is well understood, the complete effects of 
artificial sweeteners on induced metabolic dynamics have yet to be fully realized. Recent 
findings have demonstrated saccharin and ace K to promote new adipocyte growth,169 
and preliminary studies in adipocytes displayed differences in amino acid metabolism 
when they were incubated with artificial sweeteners as compared to glucose.170 If 
metabolic dynamics in adipocytes are altered when induced by artificial sweeteners, it 
could be assumed that skeletal muscle cells would experience similar changes.  
To examine altered metabolism dynamics induced by artificial sweeteners in 
skeletal muscle, an in vitro assay should be employed initially. This would avoid the 
complex responses due to interworking bodily systems often seen in in vivo experiments, 
and thus skeletal muscle cell’s sole response to all stimuli could be examined. The 
biological model proposed would be an immortal mouse skeletal myoblast cell line, 
C2C12. This cell line was derived from a C3H mouse donor’s satellite cells in the thigh 
muscle.177 These myoblasts are frequently used for the studies of muscle development 
and differentiation,178 and are commercially available.  
The culture and passaging of C2C12 myoblasts has been well documented.179 
Briefly, cells can be grown in an incubator at 37 ⁰C with 5% CO2. Their growth medium 
contains DMEM (Dulbecco’s Modified Eagle Medium), FBS (fetal bovine serum) and 
P/S (penicillin/streptomycin) solution. Myogenic differentiation begins immediately once 
cells reach confluency; therefore additional collections of myoblasts can be regenerated 
from the immortal cell line by passaging cells into new culture dishes prior to reaching 
confluency. The original immortal line and new passages can be stored long term by 
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freezing in liquid nitrogen. Cell viability can be determined by fluorescein diacetate 
(FDA) staining. FDA is a non-fluorescent compound that generates a fluorescent signal 
only once it is taken up by mammalian cells and has the acetate groups removed by active 
intracellular enzymes.180 This is an excellent method to verify cell viability as cells must 
be active in order to generate a fluorescent signal under confocal microscopy. 
After verification of cell viability, skeletal muscle metabolism would be 
characterized. By examining the amino acid uptake/release of cells in the presence of 
either glucose or artificial sweeteners, the differences these stimuli have on the overall 
metabolism of skeletal muscle cells can be determined. Upon reaching confluency, the 
cells can be incubated in an excess of glucose for 30 minutes. Post incubation, the 
incubation medium will be collected and transferred to an Eppendorf tube. A 
microdialysis probe will be placed in the Eppendorf tube to sample small molecule 
analytes for offline analysis by high-speed CE. This entire procedure would then be 
repeated, incubating muscle cells with a variety of artificial sweeteners (ace K, saccharin, 
aspartame, fructose, steviol), testing all stimuli at varying concentrations. These offline 
studies will then allow for the determination of overall amino acid metabolism from 
muscle cells as a result of incubation with artificial sweeteners versus glucose. 
Following the characterization of skeletal muscle cell’s overall amino acid 
uptake/release induced by glucose or artificial sweeteners, dynamic changes can 
monitored using online high-speed CE. By monitoring the dynamic changes in amino 
acid uptake/release, their rate of metabolism can be studied. Changes to this metabolic 
rate and overall outcome will provide valuable insight into how these sweeteners behave 
differently in muscle tissue.  
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Skeletal muscle cells would be grown to confluency on the surface of a 
microdialysis probe as previously described.45 Dr. Amy Stading, a previous Bowser 
researcher, was able to successfully grow astrocyte cells on the surface of a microdialysis 
probe and monitor their response to stimuli by inclusion of the stimuli into the perfusate. 
Dr. Harstad was unable to repeat this protocol with adipocytes however, presumable due 
to adipocyte cell size being so large compared to the surface area of the probe (average 
adipocyte cells are >100 µm in diameter181). This online technique would be dependent 
on myoblasts adhering to the microdialysis probe. The length of a C2C12 myotube was 
found to be 130-520 µm.182 Adjustments could be made to the probe size to make 
adhesion more attainable. If optimization of this in vitro protocol was unsuccessful, 
online analysis would have to proceed with myoblasts cultured in a cell flask, and sample 
of cell media collected at specific time-points post incubation. Currently assuming that 
myoblast adhesion is feasible with protocol optimization, the microdialysis probe would 
collect dialysate to monitor the basal uptake/release of skeletal muscle cells. After several 
basal recordings have been completed to establish a baseline, a stimulation will be 
administered to the cells by inclusion into the perfusate flown through the probe. Stimuli 
will include glucose, ace K, saccharin, aspartame, fructose and steviol. This dynamic 
information will provide insight into the rate of metabolism and metabolic changes that 
occur within skeletal muscle when exposed to artificial sweeteners as opposed to glucose.  
Following analysis of the in vitro assay, experiments would be reproduced in vivo 
in the skeletal muscle of the hind-limb quadriceps. This future direction will provide 
fundamental information regarding the metabolism dynamics of skeletal muscle exposed 
to artificial sweeteners. Complete understanding of skeletal muscle metabolism when 
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exposed to artificial sweeteners, as is common during a caloric-restricted diet, is critical 
for capitalizing on the prominent role of skeletal muscle in resting energy expenditure for 
combating obesity. This work will provide valuable information regarding the dynamics 
and overall metabolism of amino acids by skeletal muscle induced by artificial 
sweeteners as compared to glucose. 
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